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Abstract 
Introduction 
Breast cancer is the most common cancer in the UK with around 54,900 new 
cases diagnosed each year and 11,400 breast cancer deaths reported in 2016.  
Early diagnosis of breast cancer and personalised treatment strategies lead to 
a more favourable outcome. Biomarkers are essential for disease management 
in terms of risk calculation, response to treatment and disease outcome.  
The aim of this study has been to assess whether two variable number tandem 
repeats (VNTRs) may help to modify prediction of breast cancer risk in patients 
with pathogenic germline variants in the BRCA1 and BRCA2 tumour 
suppressor genes. I therefore explored the polymorphism of the AAAG VNTR 
in the 5′ untranslated region (UTR) of the oestrogen related receptor γ 
(ESRRG) gene and a 15 bp VNTR located in the internal promoter region of 
the MIR137 gene as both genes are implicated in breast cancer. Reporter 
gene analysis was performed on the ESRRG AAAG VNTR to observe the 
effects of varying repeat lengths on differential expression of the gene under 
basal conditions and following exposure to oestrogen in a luciferase reporter 
gene assay. VNTRs are often regulatory in nature therefore they may show 
insight into pathways underlying cancer. 
  
Method 
The ESRRG AAAG and MIR137 VNTRs were explored by genotyping analysis 
on germline DNA in a female breast cancer cohort containing BRCA1/2 
positive, BRCA1/2 negative breast cancer patients, and a group of healthy 
controls. The variance of ESRRG AAAG VNTR copy number and its effect on 
gene transcription with oestrogen stimulation was assessed in a reporter gene 
assay in a breast cancer cell line (MCF7).  
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Results 
MIR137: MIR137 VNTR analysis revealed a significant difference in repeat 
distribution between BRCA positive and BRCA negative patients and was 
significantly different between BRACA1 and BRACA2 germline mutation 
carriers using clump statistical analysis. 
ESRRG AAAG VNTR: nine different allele variants of the AAAG repeats were 
observed. The longer copy numbers were more prevalent in the cancer free 
control group whereas the shorter copy numbers were associated with 
BRCA1/2 positive cases. Nine copies of the AAAG VNTR showed significantly 
enhanced reporter gene activity with oestrogen exposure in MCF-7 breast 
cancer cells. 
 
Conclusion 
Significant differences in MIR137 VNTR length were found between  BRACA1 
and BRACA2 germline mutation carriers and wild type controls. The ESRRG 
AAAG VNTR showed significant distribution differences between the BRCA1/2 
positive and control groups.  
An increase in ESRRG transcription on exposure to oestrogen in the presence 
of 9 copies of the VNTR may relate to an increased cancer risk. This may be 
influenced by environmental factors which contribute to GxE interactions in 
cancer. 
Our findings support the role of the ESRRG AAAG VNTRs as a potential 
biomarker in the prediction of breast cancer risk in BRCA1/2 pathogenic 
germline variant carriers and may also add information to genetic risk scores 
which can further stratify treatment and surveillance in high risk individuals. 
Although significant differences were found between groups in MIR137 VNTR 
the sample sizes were small therefore these results should be interpreted with 
caution. This data should be extended and validated in a larger cohort. 
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1 Introduction 
1.1 Breast Cancer Demographics in the UK 
Breast cancer is a complex disease that is caused by abnormal growth and 
uncontrolled division of cells within the terminal duct and lobules of the breast. 
It occurs mostly in women but men can also be affected. Although there is an 
appreciable group of individuals with a hereditary predisposition for breast 
cancer, the majority are sporadic cases.  
Breast cancer is the most common cancer in the UK affecting almost 54,800 
women and 390 men each year and is the leading cause of death amongst 
British women. One in eight women develop breast cancer in the UK during 
their lifetime compared to one in 870 men (CRUK, 2017).  
 
1.2 Risk Factors for Breast Cancer  
The risk of developing cancer is multifactorial and associated with genetics, 
age and exposure to risk factors. A gene versus environment (GxE) approach 
should therefore be adopted when assessing risk factors for breast cancer 
prediction. Modifiable risks can be altered by changes in lifestyle. In the UK 
27% of breast cancers in females are lifestyle related (CRUK, 2017).  
 
1.2.1 Modifiable Risk Factors 
1.2.1.1 Oral Contraceptive Pill and Breast Cancer  
Breast cell proliferation increases during oral contraceptive (OC) use. 
Oestrogen which is also present in OCs triggers mitosis in epithelial cells in the 
breast. This may be a harmful side effect which could imply that the OC 
behaves as a tumour promoter (Isaksson et al., 2001). The exact mechanism 
of carcinogenesis with OC use is not clear. The current generation of OC 
preparations are linked with an increased breast cancer risk in an oestrogen 
and progesterone dose dependent manner. Women aged 20–49 years are 
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particularly vulnerable to it (Beaber et al., 2014). The risk does however 
diminish after OC use has been stopped with no apparent residual risk beyond 
10 years following cessation (Collaborative Group on Hormonal Factors in 
Breast, 1996).  
 
1.2.1.2 Hormone replacement therapy and breast cancer  
The risk of postmenopausal breast cancer increases with the use of hormone 
replacement therapy (HRT). Combined forms of HRT containing both 
oestrogen and progestogen (a synthetic form of progesterone) rather than 
oestrogen alone further increase the risk. Duration of HRT use up to 15 years 
also increases the relative risk. This information was reported by Jones et al 
who conducted follow up on their investigated cohort and were also mindful of 
each woman’s potential change in HRT history. Only women with a known age 
at menopause as opposed to inferred age were included in their study (Jones 
et al., 2016). Inferred age refers to women with artificially induced  menopause 
such as after a hysterectomy rather than as a physiological progression. This is 
important as it eliminates uncertainties in hormone levels. 
 
1.2.1.3 Breastfeeding and Breast Cancer  
Women who have breastfed reduce their breast cancer risk by 22% compared 
with women who have no breastfeeding history. This risk is further reduced 
with longer periods of breastfeeding (Lambertini et al., 2016). Breastfeeding 
reduces ER/PR positive and triple-negative (ER-/PR-/HER2-) breast cancer 
risk by 23% and 21% respectively. It does not however seem to have an effect 
on HER2 positive breast cancer. The association between breastfeeding and 
cancer may be linked with the presence of lactation-induced amenorrhea which 
reduces exposure to endogenous sex hormones (Dontu et al., 2004). 
 
1.2.1.4 Physical activity and Breast Cancer  
In the UK 3% of all female breast cancers are attributed to inadequate physical 
activity defined as less than 150 minutes of moderate activity per week. Every 
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additional 2 hours per week of moderate vigorous activity can reduce the risk of 
breast cancer by 5% (Wu et al., 2013). This can be explained partly by the fact 
that high levels of physical activity lower the levels of sex hormones 
(oestradiol) resulting in lower risk of breast cancer (Parkin, 2011). 
 
1.2.1.5 Smoking and Breast Cancer  
A history of smoking is linked with an increase in breast cancer risk. The risk is 
present whether smoking was commenced prior to or post first full term 
pregnancy (FFTP). Although the risk is higher if smoking occurred pre 
pregnancy. Breast tissue prior to FFTP is undifferentiated and more sensitive 
to carcinogen exposure (Ponten et al., 1990). A higher number of pack years 
(unit of measurement of amount of cigarettes smoked by a person, calculated 
by multiplying the number of packs of cigarettes smoked per day by the 
number of years the person has smoked) also increased the risk of breast 
cancer (Catsburg et al., 2015).  
 
1.2.1.6 Alcohol and Breast Cancer  
Consumption of alcohol has been linked to breast cancer. In the UK 11% of all 
breast cancers in women are linked to alcohol (Allen et al., 2009). In the USA, 
the Nurses’ Health Study reported that breast cancer risk increases by 7-10% 
with each unit of alcohol consumed per day and this increased to 15% when 
the intake increased to 4 to 9 units per week compared with women who had 
never consumed alcohol (Chen et al., 2011b). Both premenopausal and 
postmenopausal women who drink have an increased risk of breast cancer 
compared to teetotal women (Seitz HK, 2012). Alcohol consumption has been 
shown to moderately increase the levels of oestrogen (Rinaldi et al., 2006). In 
vitro studies have also revealed increased transcriptional activity of the 
oestrogen receptorα (ERα). This may alter sensitivity of breast tissue to 
oestrogen resulting in enhanced ER levels and proliferation in ER positive cell 
lines (Singletary et al., 2001).  
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A positive correlation has been made linking alcohol consumption with 
oestradiol, oestriol and oestrone levels. The presence of oestriol and oestrone 
have not been consistent between study groups but the elevation of oestradiol 
has been a common finding (Hartman et al., 2016; Hirko et al., 2014; 
Reichman et al., 1993). The mechanisms by which alcohol consumption may 
be linked to oestrogen levels and hence breast cancer risk however remain 
unclear.  
Mechanisms suggested by which alcohol may increase oestrogen levels 
include the stimulation of oestrogen production (Rettori and McCann, 1997; 
Sierksma et al., 2004) or inhibition of oestrogen degradation (Eagon, 2010). 
Chronic alcohol consumption increases the activity of aromatase which is the 
enzyme responsible for converting testosterone to oestrogen. This results in a 
fall in testosterone levels and a rise in oestrogen concentration with alcohol 
consumption (Sierksma et al., 2004). Alcohol may also enhance oestrogen 
production by inhibition of melatonin secretion (Stevens et al., 2000) or by 
interfering with the pituitary gland’s release of luteinizing hormone which is 
responsible for the release of oestradiol from the ovaries (Rettori and McCann, 
1997). Alcohol on the other hand may  also inhibit oestrogen degradation by 
inactivation of the enzymes sulfotransferase and 2-hydroxylase (Eagon, 2010). 
 
1.2.1.7 Breast Cancer and Obesity 
Twenty six percent of the UK population are obese, with an alarming increase 
in childhood obesity. This could translate into a future increase in obesity 
associated breast cancer risk. (NHS, 2018). There is an increased risk of 
breast cancer in postmenopausal women with an increased body mass index 
(BMI) who have never taken hormone replacement therapy. This is due to an 
increase in oestrogen exposure, particularly oestradiol (Key et al., 
2003),(Nassir, 2012)  This risk increases with increasing BMI in this group 
(Reeves et al., 2007).  
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1.2.2 Non Modifiable Risk Factors 
1.2.2.1 Aging, Menopause and Breast Cancer  
The risk of a woman developing cancer increases with age. Reaching the 
menopause after the age of 55 is associated with an increased risk of breast, 
ovarian, and uterine cancers. This risk increases further in women who reach 
early menarche (start of menstruation) before the age of 12 years. This 
extends oestrogen exposure increasing breast cancer risk (Surakasula et al., 
2014).  
 
1.2.2.2 Menarche, Pregnancies and Breast Cancer 
Breast tissue undergoes rapid cellular proliferation between menarche and 
FFTP, and risk increases rapidly until final differentiation with first pregnancy 
(Colditz et al., 2014). During this time period the breast tissue is particularly 
vulnerable to carcinogenic stimuli, as already mentioned (1.2.1.5). Following 
differentiation cells become less sensitive to carcinogens. Breast cancer 
models show that risk is determined by early life events, therefore preventative 
strategies should be considered early (Colditz and Frazier, 1995). Menarche 
leads to the onset of the ovulatory cycles and oestrogen exposure leading to 
increased mammary cell proliferation. Early menarche activates proliferation at 
a younger age (Rosner et al., 1994). The risk of breast cancer therefore 
increases with a longer interval between menarche and FFTP (Li et al., 2008). 
This may lead to promotion and progression of breast cancer several years 
later (Ponten et al., 1990). This risk has a greater effect on postmenopausal 
breast cancer. However, the protective effect of multiparity is stronger on 
postmenopausal breast cancers (Clavel-Chapelon and Gerber, 2002). In a 
study, there was a 25% reduction in luminal breast cancer risk in parous 
women compared to a 15% increase in risk in woman with higher age at FFTP 
(Colditz and Frazier, 1995; Pike et al., 1983).  
  14 
1.2.2.3 Breast Density and Breast Cancer 
Breast density is genetically defined as shown in twin studies which reported 
that the variability in breast density was 53-63% (Boyd et al., 2002; Ursin et al., 
2009). Higher breast density is linked with breast cancer. Dense breast tissue 
is composed of more connective and epithelial tissue than fat (McCormack and 
dos Santos Silva, 2006). Age, parity (number of viable pregnancies), and 
menopausal status account for around 20 to 30 % of causes of breast density 
variability (Vachon et al., 2015). A quarter of all single nucleotide 
polymorphisms (SNPs) also associated with breast cancer are linked to breast 
density. An example of this is the SNP ZNF365 which is associated with both 
mammographic density and breast cancer risk (Lindstrom et al., 2011; Odefrey 
et al., 2010). 
 
1.2.2.4 Ionising Radiation and Breast Cancer 
Radiation exposure (medical and natural (background) radiation) accounts for 
approximately 1% of female breast cancers in the UK (Parkin, 2011). Women 
who have received radiotherapy for breast cancer are at a 9-11% higher risk of 
developing breast cancer in the contralateral breast compared with women 
who have had surgery (Berrington de Gonzalez et al., 2010; Neta et al., 2012). 
Breast cancer risk is however small in women under the age of 75 years 
receiving diagnostic x-rays (0.1%) (Berrington de Gonzalez and Darby, 2004) 
and mammograms (0.03-0.06%) in screening programs (Berrington de 
Gonzalez et al., 2010; Neta et al., 2012). 
 
1.2.2.5 Oestrogen  
Oestrogens are natural hormones involved in the promotion and proliferation of 
normal and neoplastic breast tissue (Bonkhoff and Berges, 2009; Stingl, 2011).  
There are 4 types of oestrogen: oestrone (E1); oestradiol (E2); oestriol (E3) 
and oestetrol (E4). Oestrone is found in most tissues of the body but is 
predominantly found in fat in post-menopausal women. It can be converted to 
  15 
oestradiol and vice versa. Oestradiol is the most potent oestrogen and along 
with oestrone is associated with risk of breast cancer (EHBCC-Group et al., 
2011; EHBCC-Group et al., 2013). There is less production of oestrone and 
oestradiol during pregnancy resulting in a protective effect on breast cancer 
risk. Oestetrol and oestriol (a degradation product  of oestradiol) are only found 
during pregnancy (Ali et al., 2017; Liu et al., 2015). 
 
The main oestrogen in women is oestradiol which is vital for the development 
and maintenance of the female reproductive system and sperm production in 
men. Oestradiol is also important in the physiology of bone, the cardiovascular, 
immune and central nervous systems. Alterations in oestrogen levels can lead 
to diseases such as breast and endometrial cancer, coronary heart disease, 
osteoporosis as well as a decline in cognitive function. The effects of oestradiol 
are converted by the nuclear oestrogen receptors alpha and beta (ERα and 
ERβ) (Giguere, 1999). In post-menopausal women oestrogen synthesis is 
taken over by the adrenal glands and adipose tissue once the ovaries stop 
producing oestrogen (Cuzick et al., 2011; Santen et al., 2009).  
There will be further details on the interaction of oestrogen with the oestrogen 
receptor and oestrogen related receptors throughout the thesis. 
 
1.3 Breast Cancer Screening 
Early diagnosis of breast cancer is crucial as detection at an advanced stage 
leads to less favourable outcomes (Fisher et al., 2015). In the UK currently 
breast screening is conducted between the ages of 50 and 70 years. In some 
regions screening is performed between the ages of 47 years and 73 years as 
a trial. Women are invited to receive a mammogram every three years. Breast 
screening will pick up 95% of breast cancers and will detect lesions at a much 
earlier stage than clinical examination. One in 25 women will be called back for 
further investigation following screening and four of these women will be 
diagnosed with breast cancer. Almost 79% of these detected cancers are 
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invasive breast cancers, and 21% are in-situ or micro-invasive (BrSP, 2015; 
Public Health England, 2017a). Some women who may be considered to be at 
a higher risk of developing breast cancer may be screened at a younger age 
due to a family history of breast or ovarian cancer. This group are seen at 
family history clinics and besides a history and examination they will be 
screened with MRI scans or mammographic imaging (Public Health England, 
2016).  
 
1.4 Family history clinic 
A hereditary predisposition for breast and ovarian cancer is suspected with the 
presentation of: a personal history of early-onset breast cancer (≤ 45 years of 
age); a personal history of triple-negative breast cancer (≤ 60 years  of age, this 
breast cancer subtype is mostly associated with pathogenic BRCA1 germline 
variants); a family history of first- or second-degree relatives with breast or  
ovarian cancers (or other cancers linked to breast or ovarian cancer genes 
(section 1.6.1); or a personal history of male breast cancer (Graffeo et al., 
2016). Patients with these findings are referred to a family history clinic. 
 
A study by Walsh et al. highlights the complexity of breast cancer genetic 
mutations even in increased risk groups such as the Ashkenazi Jewish 
population. In this group half the women with mutations in either of the two 
BRCA genes did not have an associated family history. This was thought to be 
as a result of the mutation being acquired by the father coupled with small 
family units culminating in a less obvious inherited mutation (Walsh et al., 
2017). The  incidence of male breast cancer is much lower than that of females 
even in male BRCA1/2 mutation carriers (section 1.6.2) (Tai et al., 2007).  
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1.5 The burden of being a BRCA pathogenic mutation 
carrier 
The detection of a germline BRCA1/2 mutation leads to the following treatment 
options: surveillance, hormone therapy or prophylactic (risk reducing) 
mastectomy. The choice of risk reducing strategy is highly personal with 
several factors involved in reaching a decision. In 2017, Johns et al (Johns et 
al., 2017) explored the factors influencing the risk reducing decisions made by 
women who were found to have a BRCA1/2 germline mutation. Younger 
women (below the age of 30 years) were more likely to opt for surveillance 
rather than surgery. This decision may have been influenced by the desire to 
breast feed or for the purpose of body image. A third of female BRCA mutation 
carriers chose risk reducing surgery over surveillance before the age of 50 
years. This decision was strongly influenced by whether a relative had been 
diagnosed with breast cancer or who had died of the disease (Johns et al., 
2017). A prophylactic mastectomy will reduce the risk of developing cancer but 
may also come with complications of surgery and psychological and emotional 
problems relating to body image. Post-operative complications following a 
mastectomy include pain, infection, a seroma (serous fluid collection at the site 
of surgery with the potential to become infected), bleeding, implant failure (if 
immediate reconstruction performed at time of mastectomy), excessive 
scarring and lymphoedema (swelling of the arm due to damage to the 
lymphatic drainage system) (Barton et al., 2005; West, 2004). On the other 
hand, choosing to be monitored for breast cancer means that the individual is 
living with the probability of developing breast cancer on a daily basis, which 
can also be a great psychological burden. The relative risk of developing 
breast cancer is highest between the ages of 30-60 years therefore this time 
period would result in the most benefit from risk-reducing mastectomy (Easton 
et al., 2015).  
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1.6 Genetic Factors 
Five to ten percent of patients with breast cancer have an underlying genetic 
mutation (Couch et al., 2014). A common disease phenotype featuring within a 
family may be due to genetic mutations, however this may also reflect a 
common life-style and environment (Mavaddat et al., 2010). Hereditary breast 
cancer was first described by the French physician Pierre Paul Broca in 1866 
based on personal involvement. Broca described the first pedigree of 
inheritable breast cancer when his wife developed breast cancer at a young 
age as did four generations of her family (Krush, 1979; Nielsen et al., 2016). 
1.6.1 Hereditary breast cancer syndromes 
Several genes are now known to be linked to defined hereditary breast cancer 
syndromes. These include Cowden (PTEN), Li-Fraumeni (TP53), Peutz-
Jeghers (STK11 mutation), Lynch (MLH1, PMS2, MSH2, MSH6, PMS2) 
(Roberts et al., 2018) and hereditary diffuse gastric cancer (CDH1 mutations) 
syndromes (Berliner et al., 2013). A subgroup of Fanconi anaemia (D1) with a 
susceptibility to childhood tumours is associated with bi-allelic germline 
mutations in BRCA2 (Howlett et al., 2002). Another high-risk gene which is 
associated with breast cancer is ‘partner and localizer of BRCA2’ (PALB2) 
which accounts for 1–2 % of inherited breast cancer cases. PALB2 encodes a 
protein which is involved in BRCA2-mediated DNA repair by promotion of 
localisation and stability of BRCA2. Moderate risk genes which give a relative 
risk of breast cancer of 2-3 fold include CHEK2 and Ataxia telangiectasia 
mutated (ATM). They represent around 5% of inherited breast cancer cases 
and have not been adequately explored as potential risk predictors (Eccles et 
al., 2013). CHEK2 is a tumour suppressor gene that encodes CHK2, a 
serine/threonine kinase. It plays a pivotal role in DNA repair, cell cycle 
regulation and apoptosis (Apostolou and Papasotiriou, 2017). An 
abnormal expression of CHEK2 may therefore result in breast cancer 
(Dufault et al., 2004). DNA double strand break leads to an activation of 
ATM which phosphorylates CHK2 at Thr68. This induces CHEK2 
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dimerization and activates it’s enzymatic activity.  CHK2 then induces 
DNA double-strand break repair by phosphorylating BRCA1 and BRCA2 
(Bartkova et al., 2008; Magni et al., 2014). 
Most of the pathogenic mutations of CHEK2 consist of small deletions or 
insertions that result in translation of a truncated protein. Carriers of 
truncating mutations with a family history of breast cancer have a greater 
risk of developing breast cancer (Cybulski et al., 2011; Weischer et al., 
2008). This risk is unaltered in individuals who are also BRCA1 and 
BRCA2 mutation carriers as BRCA1, BRCA2 and CHK2 have the same 
signaling pathways in common (Meijers-Heijboer et al., 2002). The 
incidence of these mutations are variable in different populations. In the 
Ashkenazi Jewish population three founder mutations have been 
reported (King et al., 2003). In view of the many genes involved in breast 
cancer multigene panel testing is an efficient and cost effective technique 
for testing many genes simultaneously (Girardi et al., 2018; Prapa et al., 
2017). 
 
1.6.2 BRCA1 and BRCA2 Genes  
In 1994 the BRCA1 gene (17q21, chromosome 17: base pairs 43,044,294 to 
43,125,482) (Miki et al., 1994) was linked to hereditary breast and ovarian 
cancer and the link to BRCA2 (13q12.3, chromosome 13: base pairs 
32,315,479 to 32,399,671) was made the following year (Wooster et al., 1995).  
Mutations in BRCA1 and BRCA2 mutations are inherited in an autosomal 
dominant pattern (Easton, 1999). In patients carrying a germline mutation of 
BRCA1/2 a ‘second hit’ in the non-mutant allele leads to a loss of a functional 
gene product as described in the Knudson double hit model (Knudson, 1971). 
Loss of heterozygosity (LOH) is the common pathomechanism 
underlying carcinogenesis in BRCA1/2 mutation carriers (Osorio et al., 
2002). 
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BRCA1 and BRCA2 genes are tumour suppressor genes. BRCA1 and BRCA2 
are involved in DNA double strand break repair through homologous 
recombination and therefore of pivotal importance in the maintenance of 
genomic stability (O'Donovan and Livingston, 2010). A loss of function is 
directly linked to carcinogenesis (Ahn et al., 2007). They are further involved in 
cell cycle checkpoint control and regulation of mitosis (Joukov et al., 2006). 
The risk of breast cancer increases when a germline mutation in the BRCA 
gene leads to a truncated or inactivated protein (Easton, 1999).  
While BRCA1/2 germline mutation carriers are at significantly increased risk for 
developing breast and/or ovarian cancer, penetrance is incomplete 
(Kuchenbaecker et al., 2017). Penetrance is highly variable between carriers of 
identical mutations which implies the involvement of genetic and environmental 
modifying risk factors (Milne and Antoniou, 2016). 
Overall mutations in BRCA1 and BRCA2 account for 20 to 25% of all 
hereditary breast cancers but also significantly increase the risk of ovarian, 
prostate and pancreatic cancer as well as of malignant melanoma (Easton, 
1999).  
In women who are BRCA1 and BRACA2 mutation carriers 72% and 69% will 
develop breast cancer respectively by the age of 80 years (Kuchenbaecker et 
al., 2017). The lifetime risk of developing ovarian cancer in the general 
population is 1.3% however this risk increases to 44% and 17% in the 
presence of a germline mutation in BRCA1 and BRCA2 by the age of 80 years 
respectively. In males, the presence of a BRCA2 mutations increases the 
overall lifetime risk of 0.1% for breast cancer up to 8% and in the presence of a 
BRCA1 mutation to 1% (Evans et al., 2010; Tai et al., 2007).  
The aim of screening for BRCA1/2 mutations is to calculate the risk of an 
already affected individual from developing one of these cancers or a 
contralateral breast malignancy and to work towards preventing cancer in their 
unaffected relatives (Graffeo et al., 2016). 
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1.7 Microsatellites / VNTRs 
Half the human genome is composed of repetitive sequences, a subset of 
which are short tandem repeats. Most of the tandem repeats are monomorphic 
but some are polymorphic. These polymorphic repeats are ubiquitous and also 
known as variable nuclear tandem repeats (VNTRs) or microsatellites (Cui et 
al., 2016). Microsatellites occur at thousands of locations within an organism's 
genome and make up approximately 3 % of the entire genome. 
 
Microsatellites are repeats of one to six nucleotide sequences in tandem within 
DNA. They occur at a much higher frequency than SNPs in the genome of 
mammals. The term "satellite" DNA relates to initial observation that 
centrifugation of genomic DNA in a test tube resulted in 2 layers of DNA. There 
was a prominent layer of bulk DNA and a "satellite" layer of repetitive DNA 
(Ellegren, 2004; Kit, 1961). As a result of large genetic variability amongst 
humans, microsatellites may be used in forensic DNA fingerprinting (Gettings 
et al., 2015).  
 
Microsatellite instability (MSI), defined by varying repeat copy number is a  
recurrent feature in gastrointestinal (colorectal and gastric in particular), breast, 
endometrial and lung cancers (Forgacs et al., 2001) and related to mutations 
or epimutations in DNA mismatch repair proteins (MMR) (Bebenek and Ziuzia-
Graczyk, 2018; Veigl et al., 1998). Therefore the presence of MSI in several 
loci in multiple different cancers, including known tumour suppressor genes 
(e.g. PTEN), is strong evidence for a MMR deficiency and leading to a high 
mutational burden and tumour progression of these cancers (Yarchoan et al., 
2017). Alterations in repeat unit number in and around coding sequences can 
have important quantitative and qualitative effects on gene expression (Galindo 
et al., 2011) and could potentially be directly instrumental in cancer 
progression (Bontekoe et al., 2001; Fondon and Garner, 2004; Houlston and 
Tomlinson, 2001). 
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1.7.1 Microsatellites / VNTR in breast cancer 
Mutations in microsatellites have been associated with loss of function in 
different tumour suppressor genes and oncogenes (Bussaglia et al., 2000; Huff 
et al., 1995; Weitzel et al., 2000). The association of VNTRs with breast cancer 
and as modifiers of BRCA1/2 gene mutations has previously been reported in 
the context of “candidate genes” (Cui et al., 2016) and have been proposed as 
a marker of risk for breast cancer for over two decades (Cui et al., 2016; 
Galindo et al., 2011; Tamimi et al., 2003; Xiang et al., 2012; Yoon et al., 2010; 
Zhang et al., 2011). The AAAG VNTR in the 5’ UTR of the oestrogen related 
receptor gamma (ESRRG) gene in particular has been investigated in relation 
to breast cancer and will be discussed further in chapter 3. In this study we aim 
to investigate variation in AAAG VNTR length in a UK cohort of women with 
BRCA 1/2 mutations, BRCA negative breast cancer and healthy women with 
no cancer history as controls. 
 
1.8 Single nucleotide polymorphisms 
Single nucleotide polymorphisms (SNPs) are the most frequently encountered 
genetic variation found in both coding and non-coding regions of the human 
genome. SNPs which are frequently found near particular genes can be a 
marker for that gene. They can also be a marker of genes associated with a 
specific disease if only found in individuals with the disease. SNPs found in 
coding regions could change the amino acid code affecting protein function and 
disease progression (Vachon et al., 2015). 
The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have also 
confirmed a contribution of SNPs to breast cancer risk in BRCA1 carriers 
(Couch et al., 2013). Approximately 100 SNPs have now been associated with 
breast cancer risk however SNPs identified at 18 loci in 2010 account for about 
two-third of the hereditary component of breast cancer and has been referred 
to as SNP18 which is in use for risk prediction (Eccles et al., 2013; Turnbull et 
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al., 2010). This panel was also used to predict risk in BRCA2 mutation carriers 
by Ingham et al (Ingham et al., 2013).  
Antoniou et al demonstrated an association with altered penetrance in BRCA2 
mutation carriers and nine common breast cancer associated SNPs (at the 
TOX3, FGFR2, MAP3K, LSP1, 2q35, SLC4A7, 1p11.2, 5p12, 6q25.1 loci) 
(Antoniou et al., 2010; Antoniou et al., 2011). Multiple variant testing is perhaps 
even more informative for individuals attending a family history clinic who are 
found not to be BRCA mutation carriers. The majority of these women who 
receive a negative result following germline testing for BRCA1/2 only slightly 
reduce their predicted risk of breast cancer. For these women, a SNP 
Polygenic Risk Score (PRS) would provide a more meaningful result once 
BRCA1 and BRCA2 mutations have been excluded. This was highlighted by 
Evans et al who reported that the use of SNP18 PRS resulted in over half of 
BRCA negative women changing the National institute of health and care 
excellence (NICE) defined risk category (Evans et al., 2017).  
 
Genome-wide association studies (GWAS) are particularly useful for 
investigation of SNP association with disease penetrance and those frequently 
found in noncoding regions (Welter et al., 2014; Zhang et al., 2016). Next 
generation sequencing advances have made it possible to identify further 
SNPs and to analyse them in more depth (Chan et al., 2017). Panel testing of 
multiple selected SNPs in combination can therefore be substantially more 
informative of cancer risk prediction than analysis of individual SNPs. This is 
essential for stratification of disease risk and treatment provision (Vachon et 
al., 2015). 
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1.9 Oestrogen receptors and oestrogen-related 
receptors  
1.9.1 Nuclear Receptors 
Nuclear receptors are a family of transcription factors which regulate several 
genes and physiological functions in a ligand-dependent manner. Nuclear 
receptors were initially identified as hormone receptors for 17β-oestradiol, 
corticosteroids, and thyroid hormones (Becker-Andre et al., 1993; Holzer et al., 
2017). The nuclear receptors are called a super-family and consist of 48 
members and 7 subgroups formed based on their sequence similarities. The 
Oestrogen receptor like group is of particular significance to this project due to 
its link with breast pathology. This group is further divided into Oestrogen 
receptors (ERs), Oestrogen related receptors (ERRs) and 3-ketosteroid 
receptors (including androgen, progesterone, glucocorticoid and 
mineralocorticoid receptors) (Riggins et al., 2010; Roshan-Moniri et al., 2014). 
Nuclear receptors are characterised by 4 main conserved domains: the N-
terminal regulatory domain consisting of activation function (AF)1; the DNA 
binding domain; hinge domain; and ligand binding domain. The DNA-binding 
domain consists of two zinc finger domains and demonstrates affinity for 
response elements (Helsen et al., 2012; Huang et al., 2010; Mullican et al., 
2013). 
The nuclear receptors have gathered considerable research interest over the 
years for the treatment of breast cancer. The ligand binding sites have been 
found to interact with small molecules which have lead to the discovery of 
drugs which target the oestrogen receptor in breasts cancer prevention and 
treatment. These molecules act as either antagonists or agonists by competing 
with endogenous ligands (Roshan-Moniri et al., 2014). 
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1.9.2 Oestrogen receptors (ERs) 
The oestrogen receptors and oestrogen signalling pathways are involved in 
breast cancer progression (Ariazi and Jordan, 2006). Approximately 70% of 
breast cancers are oestrogen receptor positive (ER+ or ERα+) and cell 
proliferation is oestrogen-dependent (Jemal et al., 2009). These receptors 
activate gene expression in a ligand-dependent manner by acting as ligand 
regulated transcription factors. They are involved in various cellular events 
such as cell growth and apoptosis (Holzer et al., 2017; Platet et al., 2004). ERα 
represents the interface between cancer development, progression and 
treatment, this makes it the most important target in breast cancer therapy. ER 
expression in breast cancer is therefore not only a prognostic factor but also a 
very important predictive factor guiding oncological regiments. (Ariazi and 
Jordan, 2006).  
The fact that the majority of breast cancers are oestrogen receptor  positive 
(ER +) has a favourable impact on anti-oestrogen therapy in most patients as 
treatment of ER + breast cancers includes blocking oestrogen therapeutically 
(Ariazi et al., 2002). The two main principles of anti-oestrogen therapy in the 
oncological setting in breast cancer are to either inhibit oestrogen binding to 
the ER (tamoxifen) or prevent the production of oestrogen (aromatase 
inhibitors) (Howell et al., 2004). Current endocrine therapy consists of the 
selective oestrogen receptor modulators (SERMs) and aromatase inhibitors 
(AIs) (Crago et al., 2010). The SERM used most frequently in both pre- and 
post- menopausal women to treat breast cancer is Tamoxifen. Its mechanism 
of action is as an antagonist for the ER by competing with 17β-estradiol 
(Clarke et al., 2001). Aromatase inhibitor (AI) therapy is used in post-
menopausal women with breast cancer. As the name suggests, it inhibits 
aromatase which is the enzyme involved in converting androgens to oestradiol. 
The AIs therefore deprive ER+ breast cancer of oestrogen and as a result 
blocks oestrogen signalling and cell growth stimulation. AIs currently in use are 
Exemestane, Letrozole, and Anastrazole (Smollich et al., 2009). 
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Adjuvant or neoadjuvant endocrine treatment is extremely effective in the 
management of ER+ breast cancer however a third of patients do not respond 
to Tamoxifen and 70% of the remaining group are at risk of disease recurrence 
(Early Breast Cancer Trialists' Collaborative et al., 2011; Riggins et al., 2005). 
As a result of increasing drug resistance the discovery of alternative proteins 
and pathways as targets is of interest.  The ERRs are therefore being studied 
as potential alternative drug targets with the aim of reducing the incidence of 
disease recurrence through drug resistance (Early Breast Cancer Trialists' 
Collaborative, 2005; Roshan-Moniri et al., 2014). 
1.9.3 Oestrogen Related Receptor Gamma (ERRγ) 
The oestrogen related receptor (ERR) family consists of 3 isoforms: ERRα, 
ERRβ and ERRγ (Giguere et al., 1988).  ESRRA gene encoding ERRα was 
mapped to chromosome 11q12-q13, the ESRRB encoding ERRβ was located 
to 14q24.3 (Shi et al., 1997; Sladek et al., 1997) and ESRRG encoding ERRγ 
on chromosome 1q41 (Eudy et al., 1998). The ERRs share sequence 
similarities and biochemical functions with ERs. ERRs however do not bind to 
oestrogen or endogenous oestrogen receptor ligands. These receptors are 
therefore called orphan nuclear receptors (Deblois and Giguere, 2013; 
Roshan-Moniri et al., 2014) 
The ligand binding domain of the ERRs contains the activation factor-2 (AF-2) 
site which is of importance in the function of ERRs. This site is exposed as a 
result of the structure of the ligand binding domain and as a result it can bind 
coregulators in the absence of ligand binding. The consequence of this domain 
structure is a constitutively active receptor. The mediation of the Transcriptional 
properties of the ERRS is performed by coactivators (PGC-1α, SRC-1, SRC-2, 
SRC-3) and corepressors (RIP140) (Roshan-Moniri et al., 2014). ER shares 
structural overlap with ERRα and ERRγ and are therefore considered to have 
potentially similar functions in breast cancer (Roshan-Moniri et al., 2014). 
Higher ERRα expression levels have been identified in aggressive and triple 
negative breast cancers. Other associated features are high tumour grade, 
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metastasis and risk of recurrence. ERRα therefore promotes cell migration and 
invasion and is an indicator of poor prognosis in breast cancer. Inactivation of 
ERRα impairs in vitro migration of breast cancer cells (Ariazi et al., 2002; Stein 
et al., 2008; Suzuki et al., 2004; Wu et al., 2015). Upregulation of ERRγ on the 
other hand is associated mainly with ER+/PR+ breast cancers and a 
favourable outcome in breast cancer. A microsatellite within the ERRγ gene is 
the subject of this project and will be discussed further in chapter 3.  
The role of ERRβ in breast cancer is not fully understood. It is a coregulator of 
ER, mediates oestrogen response and may function as a tumour suppressor 
(Misawa and Inoue, 2015; Sengupta et al., 2014). While the exact mechanism 
of action of both ERRα & ERRγ in breast cancer is still not fully understood, 
current findings support a potential role of these receptors as therapeutic 
targets and prognostic predictors in breast cancer due to their similarities to the 
ER. 
1.9.4 Interaction between Oestrogen Receptors and Oestrogen 
Related Receptors 
ERs regulate gene expression by recruiting co-regulators to oestrogen 
response elements (EREs). This can only in part explain the effects of the 
oestrogen signal pathway. ERR and its oestrogen related response elements 
(ERRE) have been investigated as a potential for coregulatory recruitment and 
an alternative oestrogen signalling pathway (Sun et al., 2006). Coactivators 
which play important roles in ERR- mediated transcription have been found to 
be associated with both ERRs and ERs suggesting that transcriptional 
cofactors are partly shared between both receptor groups. ERRs are also 
thought to have an effect on ER-mediated signalling because ERRs can bind to 
EREs as well as ERREs (Knutti and Kralli, 2001; Lin et al., 2003; Puigserver 
and Spiegelman, 2003). 
Promising discoveries are being made in the search for an alternative 
oestrogen signalling pathway to overcome the problem of resistance to 
hormone therapy and risk prediction. The roles of the nuclear receptors are not 
fully understood therefore research continues to explore these orphan nuclear 
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receptors as well as the search for ligands. ERRs are still currently considered 
to be orphans despite the discovery of ligands for many previously orphan 
nuclear receptors now considered to be ‘adopted’ (Benoit et al., 2006) 
1.10 Micro RNAs 
MicroRNAs (miRs) are a large class of non-coding RNAs regulating many 
biological processes (Bartel, 2004). miRs are typically 21-25 nucleotides long. 
Genes encoding miRs have been located in exonic, intronic (i.e. in host genes) 
and intergenic DNA (Rodriguez et al., 2004). Micro RNA genes are transcribed 
in the nucleus to pri-miRNA by RNA polymerase II (Cullen, 2004) and then 
processed by DROSHA, an RNaseIII to pre-miRNA which is then exported 
from the nucleus by exportin-5 into the cytosol (Lund et al., 2004; Wu et al., 
2000). There pre-miRNA is cleaved by a second RNAse III, DICER to form 
miRNA duplex which after unwinding and degradation of the passenger strand 
forms the mature RNA interference induced silencing complex (RISC) 
(Hutvagner et al., 2001; Martinez et al., 2002). The mature miRNA-RISC 
complex then binds to the 3'-untranslated region (3'-UTR) of mRNA transcripts 
leading to mRNA degradation and herein post-transcriptional repression or 
RNA and catalytic RNA cleavage (Ambros, 2004; Filipowicz et al., 2008; 
Navarro and Lieberman, 2010). Micro RNAs regulate a wide range of cellular 
functions such as development (Sayed and Abdellatif, 2011), cell proliferation 
(Lenkala et al., 2014), cell differentiation (Ivey and Srivastava, 2010), apoptosis 
(Su et al., 2015), signal transduction (Inui et al., 2010) and cell cycle (Bueno 
and Malumbres, 2011). MicroRNAs may act as tumour suppressors or 
oncogenes (Dyrskjot et al., 2009; Zhang et al., 2014).  
The role of miR137 in malignancies will be discussed in the results chapter as 
it is of particular interest in this project due to its role in breast cancer and its 
potential as a biomarker. Approximately 50 genes have been identified to be 
directly regulated by miR137 and found to be involved with the pathways 
mentioned above (Wright et al., 2013). A list of targets of miR-137 are outlined 
in table 1.1 adapted from Mahmoudi et al (Mahmoudi and Cairns, 2017). 
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2 Materials and Methods 
2.1 Ethics 
Ethical approval was granted by the Central Manchester Research Ethics 
Committee reference number 10/H1008/24 for the collection and analysis  of 
patient DNA and associated clinical information for the purpose of research. 
 
2.2 Materials 
2.2.1 Human DNA samples 
Genomic DNA was extracted and provided by the National Genetics 
References laboratory, St Mary’s Hospital Manchester. The cohort comprised 
of four groups with 200 female patients in each. The four groups consisted of : 
patients with wild type alleles of BRCA1 and BRCA2 (BRCA negative) all with 
breast cancer; patients with proven BRCA1 or BRCA2 germline mutations 
some of whom had breast cancer; and a control group of age matched tumour-
free women with wild type alleles for BRCA1 / BRCA2 (control) . 
Additional complete clinical details were not available by the time of completion 
of this project. Details of the specific types of the BRCA mutations were not 
provided and due to time constraints with the project these mutations were not 
explored.  
 
2.2.2 Assessment of DNA quality by spectrophotometry  
DNA concentration and quality were assessed by measuring absorbance at 
260 and 280 nm using a NanoDrop 2000c spectrophotometer. The quality was 
considered appropriate when the ratio A260/A280 nm was greater than 1.75; A280 
of 0.1 - 1 was regarded as suitable for further processing.  
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2.2.3 Human cell line 
2.2.3.1 MCF-7 Cells 
This cell line was kindly provided by Professor Rudland and Professor Palmieri 
from the Royal Liverpool University Hospital.  
MCF-7 cells were first described by Dr Herbert D. Soule. He successfully 
cultured metastatic cancer cells from the malignant pleural effusion of a 
metastatic breast cancer in an American nun (Sister Catherine Frances 
Mallon). Herbert D. Soule successfully cultured these cells overcoming 
difficulties with fibroblast overgrowth and nutritional environment experienced 
at the time by other scientists.  
The resulting cell line was called MCF-7, named after the Michigan Cancer 
Foundation where Dr Soule was based and represented his seventh attempt at 
generating a cancer cell line (Lee et al., 2015a). 
 
 
2.2.4 Commonly used buffers and cell culture reagents 
2.2.4.1 LB Broth 
LB broth, 2.5%  (Fluka Analytical) in water. The 25 g LB broth was dissolved in 
1000 ml of distilled water, autoclaved and stored at room temperature. The 
composition of the LB broth per ml is as follows 
10 mg Tryptone 
5 mg yeast extract 
10 mg sodium chloride 
 
2.2.4.2 LB Agar 
LB agar, 4% (2.5% LB broth (see above), 1.5% bacteriological agar (Fluka 
Analytical). 15 g of bacteriological agar was dissolved in 1000 ml of 2.5% LB 
broth (see above). The LB agar was autoclaved and stored at room 
temperature. 
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2.2.4.3 5X TBE Buffer  
Tris base, 108 g  (Sigma-Aldrich), 55 g boric acid (Sigma-Aldrich), 5.84 g 
EDTA (Sigma-Aldrich) was made up to a volume of 2000 ml with distilled 
water. 
 
• Ampicillin (75µg/ml) / Kanamycin (25 µg/ml) stock solution.  
• Insulin  
Insulin solution human 100 μg/mL in PBS, pH 7.2 stock solution (Sigma-
Aldrich; 11061-68-0)  
• Trypsin (Sigma-Aldrich) 
• Oestrogen 
17β-estradiol (1 mg/ml in ethanol); final concentration of 10nM dissolved 
in DMEM. 
• Freezing Media for eukaryotic cells  
The freezing media was composed of 90% foetal bovine serum (Sigma-
Aldrich) and 10% Dimethyl sulfoxide (DMSO) (Sigma-Aldrich). 
• 1x PBS (phosphate buffered saline; Sigma-Aldrich) 
 
2.2.5 Cell culture media 
2.2.5.1 Media for MCF-7 cells (MCF-7 media) 
Cells were cultured in Dulbecco’s modified Eagles medium (DMEM) with 
4500 mg glucose/L (Sigma-Aldrich, cat no D5796), 10% foetal bovine serum 
(FBS; Sigma-Aldrich), penicillin (100 units per ml), streptomycin (0.1 mg/ml) 
and insulin (10 µg/ml). 
 
2.2.5.2 Stripped Media for MCF-7 cells (MCF-7 stripped media (oestrogen 
free media)) 
Stripped media consisted of DMEM with 4500 mg glucose/L free of phenol red 
(Sigma-Aldrich, cat no D1145), 5% (v/v) charcoal stripped FBS (Sigma-
Aldrich), penicillin (100 units per ml), streptomycin (0.1 mg/ml) and L-glutamine 
(2mM) (Sigma-Aldrich). Phenol red has oestrogenic activity and stimulates the 
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proliferation of oestrogen receptor positive MCF-7 breast cancer cells (Berthois 
et al., 1986). Phenol red in tissue culture media acts as a weak oestrogen: 
Implications concerning the study of oestrogen-responsive cells in tissue 
culture (Berthois et al., 1986) and charcoal treatment of the serum causes 
endogenous hormone deprivation (Sikora et al., 2016). 
 
2.3 Genotyping 
2.3.1 Polymerase chain reaction  
2.3.1.1 Polymerase chain reaction for genotyping 
Polymerase chain reaction (PCR) (Kleppe et al., 1971; Mullis et al., 1986; 
Mullis and Faloona, 1987) was performed to amplify VNTRs within the DNA of 
the Manchester cohort of breast cancer subjects and controls using Go Taq 
flexi DNA polymerase (Promega). 
A thermocycler: QB-96 (Quanta Biotech) and Peqstar 2X (Peqlab) were used 
for PCR. The optimisation process was carried out by performing temperature 
gradient PCRs. The PCR protocol for each gene is outlined in the table below.  
 
2.3.1.2 PCR for AAAG VNTR in ESRRG 
The sequence of interest in the 5’ UTR of the oestrogen receptor gamma 
gene surrounding the ‘AAAG’ tetramer tandem repeat defined by genomic 
position GRCh38.p12, Sequence ID: NC 000001.11 217053466 – 217053500 
was entered into BLAST for homology comparison: (https: //blast.ncbi.nlm. 
nih.gov/Blast.cgi). Primers were designed using UCSC genome (Hg 19) 
browser (http://genome.ucsc.edu/index.html) and Primer 3 programme 
(bioinfo.ut.ee/primer3). The primers were finally checked for specificity in the in 
silico PCR programme of the UCSC genome browser (http: 
//rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr). The designed primers were 
then produced by Eurofins (MWG).  
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ESSRG AAAG VNTR primer set: 
Forward primer: 5’-acctaggagatagaggttgc-‘3 
Reverse primer: 5’-cttcttctgcactatcaggg-‘3 
The predicted PCR product was 369 bp long (chr1:217,053 ,376-217,053,745). 
 
PCR reactions were carried out in a volume of 25 µl. The PCR master mix 
contained 5µl of 1x Go Taq flexi reaction buffer, dNTPs (400 µM), Taq 
Polymerase (0.05 U/µl), primers (0.4 µM), additional magnesium if required (2 
mM) and DNA (5 ng/µl). Reactions were initiated with a 300 sec enzyme 
activation and DNA denaturation step at 95°C followed by 35 cycles consisting 
of an initial denaturation step at 95°C (30 sec), an annealing step at 59.3°C (30 
sec) and finalised by an elongation step at 72°C (30 sec). The reaction was 
completed by a final elongation step for 600 sec at 72°C. The PCR product 
was finally stored at 4°C (figure 2-1).  
 
 
Master mix for AAAG VNTR in ESRRG 
 Volume Concentration 
5X Go Taq flexi buffer (undyed) 5 µl 1x  
Mgcl2 (25mM) 2 µl 2 mM 
dNTP(10mM) 1 µl 0.4 mM 
Forward Primer (20 µM) 0.5 µl 0.4 µM 
Reverse Primer (20 µM) 0.5 µl 0.4 µM 
Go Taq polymerase (5 U/µl) 0.25 µl 0.05 U/µl 
Nuclease free water 14.75 µl  
DNA(5 ng/µl) 1 µl 
Final Volume 25 µl 
Master mix for each reaction (n=1) 
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Figure 2-1: ESRRG AAAG VNTR thermo cycler protocol:  Schematic 
outline of the thermo cycler protocol as described in 2.3.1.2 
 
 
2.3.1.3 PCR for MIR137 VNTR  
PCR reactions were carried out in a volume of 25 µl. The PCR master mix 
contained 5µl of 1x Go Taq flexi reaction buffer, dNTPs (400 µM), Taq 
Polymerase (0.05 U/µl), primers (0.4 µM), additional magnesium if required (2 
mM) and DNA (5 ng/µl). Reactions were initiated with a 300 sec enzyme 
activation and DNA denaturation step at 95°C followed by 35 cycles consisting 
of an initial denaturation step at 95°C (30 sec), an annealing step at 68°C (30 
sec) and finalised by an elongation step at 72°C (30 sec). The reaction was 
completed by a final elongation step for 600 sec at 72°C. The PCR product 
was finally stored at 4°C (figure 2-2).  
 
MIR137 VNTR primer set: 
MIR137-F:  5’-cacccaagaatacccgtcac-‘3 
MIR137-R:  5’-tgggagagcaccaggtaaac-‘3 
The shortest predicted PCR product was 370 bp. For each additional copy of 
the VNTR multiples of 15 bp were expected to be added to the PCR product. 
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Mastermix for MIR137 PCR (Warburton et al., 2015)  
    
 Concentration Volume 
5X Go Taq flexi buffer (undyed) 5µl 1x  
MgCl2 (25mM) 4 µl 4 mM 
dNTP(10mM) 1 µl 0.4 mM 
Forward Primer(20 µM) 0.25 µl 0.2 µM 
Reverse Primer(20 µM) 0.25 µl 0.2 µM 
Go Taq polymerase(5u/µl) 0.25 µl 0.05 U/µl 
Nuclease free water 12.25 µl  
DNA(5ng/µl) 2 µl 
Final Volume 25 µl 
Master mix for each reaction (n=1) 
 
  
Figure 2-2: MIR137 VNTR thermo cycler protocol: Schematic outline of the 
thermo cycler protocol as described in 2.3.1.3 
 
2.3.2 Agarose Gel Electrophoresis  
Gel electrophoresis was used to separate DNA fragments by size in order to 
identify PCR products and allele variants. It was also used in order to 
segregate PCR products prior to DNA extractions for cloning. The amount of 
agarose (Bioline) used was determined by the percentage of the gel required. 
Gels were varied between 0.8% and 2% depending on the fragment size.  
 
Example: 1.5% agarose gel: 0.9 g agarose powder in 60 ml 0.5x TBE buffer 
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Agarose powder was dissolved in the 0.5 x TBE and  DNA intercalating dye 
(gel red (Biotium 10000X; 0.1 µl/ml TBE) was added. The warm liquid gel 
solution was poured into a casting tray and the wells within the gel were 
created by combs placed in the tray until the gel had set at room temperature. 
The casting tray containing the set gel was placed into a gel tank filled with 0.5 
x buffer. Commonly, 15 µl of sample and 3 µl of loading dye (Promega 6x) 
were added to each well. DNA ladders of 100 bp and 1 kb (Promega) were 
used. The ladders were placed into the first and last wells of the gel. The gel 
was run in 0.5x TBE at a rate of 5 volts per centimetre.  
The fragments of DNA were separated as an electric current passed through 
the gel migrating towards the cathode. The level of separation and the speed 
at which this occurred was dependent on the size of the fragments and the 
percentage of the gel used. DNA in gels was visualised using a UV 
transilluminator (BioDoc-it Imaging system). 
 
2.4 Generation of reporter gene constructs 
The 16 copies of the AAAG VNTR in the ESRRG were excised from the pGL3-
control (pGL3C) plasmid by restriction digest and inserted it into a pGL3-
promoter (pGL3P) plasmid containing a luciferase reporter gene (figure 2.1). 
pGL3-promoter was chosen as a vector as it has been designed for cloning 
and testing putative enhancer regions. It has also previously been successfully 
used by our group (Galindo et al., 2011). 
 
 The restriction reaction was performed in a digestion mix as follows: 
       
10 x Digestion buffer 2 µl 
DNA (1 µg) x µl 
Restriction enzymes (10 U/µl)  (Acc 65I / Bgl II) 0.5 µl 
10 x BSA (10 µg/µl)  2 µl 
Nuclease free water z µl 
Final Volume 25 µl 
 
 
  38 
The digests were incubated for 4 hours at 37ºC. In brief, the enzymes used 
gave products with end overhangs for use in DNA ligation reactions. The 
digestion products were run on an agarose gel as described above, visualised 
under a UV-transilluminator and the DNA bands of interest excised from  the 
gel.  
2.4.1 Agarose gel extraction of DNA fragments 
DNA isolated from agarose gels and purified using the QIAquick Gel Extraction 
Kit (Qiagen) as outlined in the manufacturer’s protocol. In brief: the gel 
containing the DNA of interest was dissolved in the solubilisation buffer ‘QC’ 
provided by the supplier. The dissolved DNA was mounted on the filter 
columns and then purified using wash buffers provided. At the end DNA was 
eluted from the filter columns and used for further processing (i.e. ligation 
experiments) or was frozen at -20ºC.  
 
2.4.2 Ligation of DNA fragments into pGL3P reporter gene 
vector 
The digested vector and insert were used at a molar ratio of 1:3. The following 
equation was used to calculate quantities to be used. 
 
              Vector (ng) x size of the insert 
Insert (ng) = –––––––––––––––––––––––––––––––– 
                   Size of the vector (kb) 
  
 
Insert x µl 
Vector y µl 
2 x ligation buffer 5 or 10 µl (depending on final volume) 
T4 DNA ligase (100 units) 1 µl 
Nuclease free water z µl 
Final Volume 10-20 µl 
 
The above reaction was incubated at room temperature for 3 hours.  
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Figure 2.3: pGL3P construct: the multiple cloning site (MCS) highlighted with 
restriction enzyme cutting sites (Acc 65I and Bgl II) and site of AAAG insertion. 
Sequencing primers (RVprimer3 and GLprimer2, see section 2.3.7; 
sequencing) are indicated in purple. 
 
2.4.3 Transformation of DH5α  competent E. coli cells 
50 µl of DH5α competent E. coli cells (Invitrogen) were thawed on ice for each 
transformation reaction. Each 50 µl of the thawed cells were placed into a 
1.5 ml microcentrifuge tube and 5 µl (10 ng) of each ligation product were 
added to it and then mixed by gentle tapping. The reaction was incubated for 
30 min on ice and then heat shocked at 42°C for 20 sec in a water bath 
following which it was placed on ice again for a further 2 min.  950 µl of pre-
warmed LB broth was added to each tube and shook at 225 rpm for 1 hour at 
37oC in an incubator. Then 200 µl of the above mixture was spread on warmed 
LB agar plates and incubated at 37oC overnight. The plates contained 
100 µg/ml Ampicillin.  
 
2.4.4 Miniprep of plasmid DNA  
DNA was extracted from E. coli cells using QIAprep miniprep kit and was 
performed according to manufacturer’s instruction. In brief: colonies were 
picked from the LB agar plates which had been previously spread with the 
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transformation mixture. Individual colonies were picked, added to 5 ml of LB 
broth with 5 µl of ampicillin (100 µg/ml) and grown in a shaking incubator 
overnight at 37°C. DNA isolation involved lysing the bacterial culture, 
adsorption of the plasmid DNA on a silica membrane and finally elution of 
purified DNA.  
 
2.4.5 pGL3P Plasmid extraction 
Single E. coli colonies from an inoculated LB agar plate or a scraping from a 
glycerol stock of the required plasmid DNA were added to a starter culture 
consisting of 5 ml LB broth and 5 µl of ampicillin. This was placed into a 
shaking incubator set at 37°C for 8 hours. 200 µl of the starter culture was then 
added to 100 ml of LB broth and 100 µl of ampicillin the next day. This was 
grown at 37°C in a shaking incubator for 12-16 hours. The cells where then 
pelleted by centrifugation and the pellet washed with PBS. The plasmid was 
then extracted using the Qiagen plasmid maxi prep kit according to the 
manufacturer’s instructions. In brief, the cells were lysed using the provided 
lysis buffer. The lysis reaction was stopped by the addition of a neutralising 
buffer. The solution was then centrifuged and the DNA in the aqueous phase 
was transferred on the maxi prep columns. The plasmid DNA was washed and 
eluted from the columns. Isopropanol was added to the eluted DNA to 
precipitate it. The DNA was pelleted by centrifugation and washed with 70% 
ethanol to remove precipitated salt and to replace the Isopropanol. The ethanol 
was decanted and the pellet air-dried. The DNA was then resuspended in 50 µl 
of elution buffer. This process provides highly purified high yield plasmid DNA. 
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2.4.6 PCR confirmation of plasmid inserts: 
High fidelity PCR Phusion kit (Thermoscientific) was used for plasmid 
sequencing. A standard PCR master mix included: 
 Volume Final concentration 
Buffer ( 5x) 10 µl 1X 
dNTPs (10mM each) 1 µl 200 µM 
Upstream Primer (20 µM) 2.5 µl 0.5 µM 
Downstream Primer (20 µM) 2.5 µl 0.5 µM 
Nuclease free water 32.5 µl 
DNA template 1 µl 1 ng, 10 ng, 
1 pg 
Phusion DNA polymerase  0.5 µl 0.02U/ µl 
Final volume 50 µl 
 
2.4.7 Sequencing 
Plasmids were then sent for sequencing to Dundee DNA Sequencing Service 
(Dundee, UK).  
Sequencing primers (RV primer 3 (5’-CTAGCAAAATAGGCTGTCCC-3’) and GL 
primer 2 (5’-CTTTATGTTTTTGGCGTCTTCCA-3’) were used as recommended 
by the manufacturers protocol (figure 2.3). All electropherograms were 
manually read and samples with correct inserts used for further processing.  
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2.5 Cell Culture (Eukaryotic cells) 
2.5.1 Culturing of MCF-7 Cells 
MCF-7 cells were grown in modified DMEM in T175 tissue culture flasks. They 
were incubated at 37ºC / 5% CO2 and passaged once 70% confluence was 
reached. To passage the cells the media was aspirated from the T175 flask. 
The cells were rinsed with 10 ml of sterile PBS (Sigma-Aldrich, cat no D8537) 
and then with 5 ml trypsin (Sigma-Aldrich).  The trypsin was aspirated and the 
flask containing the cells was incubated at 37°C for 5 minutes until most of the 
cells lost adherence to the flask. The cells were washed from the flask with 
10 ml of media. A 25 ml pipette was used to break up clumps of cells by 
pipetting up and down. 1 ml of cell suspension in media was added to 50 ml of 
media containing 50 µl of insulin in a new 175 cm2 ventilated cap flask. 
A Mycoalert Mycoplasma Detection Kit (Lonza) was used to test the cell lines 
for mycoplasma infection every 6 months. 
 
2.5.1.1 Cell counting 
The cell count was determined prior to plating the cells for transfection 
experiments. The cells in a T175 flask were passaged at 70 % confluency up 
to the stage were the cells were harvested in 10 ml of media as explained 
(section 2.5.1). 20 µl of cell solution was removed and placed at the edge of a 
coverslip positioned over the central chamber of a haemocytometer. The cells 
then filled the central chamber. The haemocytometer was then viewed under a 
light microscope at 10x magnification. The cells were counted within a 25 
square grid in the haemocytometer which had a volume of 1 µl. Cells on the left 
and upper border of each square were included in the count whereas cell on 
the lower and right border were not. The total cell count was the number of 
cells in 1 µl of cell suspension. The number of cells in 1 ml of cell suspension 
were derived by multiplying the total cell count by 104. To convert this number 
into the number of cells per µl of cell suspension this figure was divided by 
1000. In order to calculate the amount of cell suspension to add to each well to 
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give 100,000 cells per well the number of cells per µl of suspension was 
divided by 100,000. 
 
2.5.1.2 Freezing cells for storage 
Once cells had reached 70-80% confluency in a T175 flask they were 
trypsinised as described (section 2.5.1) until the step of washing the cells off 
the flask wall. At this point the cells were washed from the flask wall with 10 ml 
of freezing media. The freezing media containing the cells were divided 
between multiple cryovials with 1.8 ml placed in each. The cryovials were 
placed into a cell freezing container (Mr Frosty, Sigma-Aldrich) containing 
isopropanol and placed in a -80°C freezer for 24 hours. After 24 hours the 
cryovials were transferred to a liquid nitrogen tank for definitive storage. 
 
2.5.2 Analysis of reporter gene expression  
2.5.2.1 Transient transfection of reporter gene constructs into MCF-7 
cells 
Twenty-four well plates were used. 100,000 cells were plated per well 
suspended in 1 ml MCF-7 media supplemented with 1 µl insulin stock solution. 
The cells were incubated at 37ºC and 5% CO2 for 24 hours. 
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2.5.2.2 Transfection 
Twenty four hours later when the cells were 70% confluent a master mix was 
made up as outlined below.  
 
Table 2-1: plasmids 
Construct Volume 
of DNA 
(1µg/µl) 
No of 
reactions 
Total 
volume 
of DNA 
 
Total 
Turbofect 
volume 2µl/ 
reaction 
Serum free 
media (make 
up to 100 µl/ 
reaction) 
HSV-thymidine 
kinase (TK) 
Renillin (20 ng/ 
µl) 
pGL3C 1 µl 5 5 µl 10 µl 476.5 µl 2.5 µl 
pGL3P 1 µl 5 5 µl 10 µl 476.5 µl 2.5 µl 
19 copy 1 µl 5 5 µl 10 µl 476.5 µl 2.5 µl 
7 copy 1 µl 5 5 µl 10 µl 476.5 µl 2.5 µl 
9 copy 1 µl 5 5 µl 10 µl 476.5 µl 2.5 µl 
16 copy 1 µl 5 5 µl 10 µl 476.5 µl 2.5 µl 
 
The media was added first and the Turbofect (transfection reagent for efficient 
transfection of plasmid DNA) last. To make up the media is required to be FBS 
free, 0.5 µl of insulin was added to 50 ml of the medium. 
The master mix solution was vortexed for 10-15 seconds then left for 20 
minutes at room temperature to allow transfection complexes to form. After 
ligation 100 µl of the master mix was added to each of the 24 wells of the plate 
and the plate was then placed back in the incubator. After 4 hours the medium 
was changed to 1ml/well of media with FBS and the plate was placed back into 
the incubator. 
 
2.5.2.3 Cell Lysis 
The final stages of the transfection was completed 48 hours after the cells had 
been transfected. Gene expression was quantified using the Promega 
luciferase assay kit and performed as recommended by the manufacturers 
protocol: the media was removed from each well containing cultured MCF-7 
cells and the cells then washed with 1 ml of sterile PBS. Cell lysis took place in 
100 µl of PLB/reporter lysis buffer. The 24 well plate was then placed on a 
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rocking platform at room temperature for 15 min. Following this 20 µl of lysate 
was transferred from each well and placed into an opaque 96 well luminometer 
plate. The first and last two wells were left empty as controls. 
 
2.5.2.4 Gene expression analysis by luciferase assay  
The 96 well luminometer plate was then placed into a Glomax luminometer 
(Promega). The injectors were flushed with distilled water, 70% ethanol, 
distilled water again, air to clean them. One of the two injectors was then 
primed with luciferase assay reagent II (LARII) and the other injector with stop 
and go. Finally the programme injected luciferase assay reagents into each 
well and luminescence from the firefly luciferase reaction and then from the 
renilla luciferase reaction was measured using the Glomax luminometer. Gene 
expression levels of the constructs were measured, normalised and compared. 
 
2.5.2.5 Treatment of cells with oestrogen 
The protocol outlined above was predominantly followed with a few exceptions: 
two days prior to plating the cells the normal media was replaced with MCF-7 
phenol red free media and charcoal stripped serum which was used for the 
remainder of the experiment. The experiment was then carried out as outlined 
(2.5.2.2) until the media was changed 4 hours post transfection when the 
following changes were performed (this media was used for the remainder of 
the experiment): 
- For the basal conditions the media was replaced with fresh media 
- For the vehicle control the media used contained 1µl/ml of molecular grade 
ethanol 
- For the treatment the media contained 10nm of 17-β-oestradiol dissolved in 
molecular grade ethanol. 
The cells in media were then incubated for 18 h following which the media was 
changed. After 48 hours of incubation the dual luciferase assay was 
performed. 
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2.6 Statistics 
2.6.1 Clump statistical analysis  
The genotyping data and allele frequency was statistically analysed using the 
clump 24 software which is available at http://www.davecurtis.net 
/dcurtis/software.html.  
The Clump statistical analysis which has been used in over 100 articles of peer 
reviewed journals (examples: (Fan and Song, 2017; Hsieh et al., 2014; Lavu et 
al., 2015; Wang et al., 2015)) is designed for maximising the probability of 
significance with data presented in sparse contingency tables where this may 
not be possible in conventional Pearson chi-squared tests. It reduces the 
power of finding associations in studies involving large numbers of rare alleles 
in highly polymorphic loci. It generates 4 chi-squared tests using the Monte 
Carlo method, three of the tests ‘clumping’ alleles together. Clumping together 
the rare alleles and also comparing them individually to the rest of the alleles 
avoids expected small values whilst detecting meaningful associations (Sham 
and Curtis, 1995). 
 
The four rows created by the program are as follows: 
T1:  The 2-by-N table provided by the user 
T2:  The original table including small numbers ‘clumped’ together 
T3:  Compares each non rare column of the original table against the total of 
all the columns 
T4:  A 2-by-2 table as a result of ‘clumping’ the columns of the original table. 
This maximises the chi-squared value 
 
2.6.2 Correlation analysis 
Correlation analysis for allele distribution between the groups was performed 
using a two-tailed Spearman rank analysis assuming non-Gaussian 
distribution. The analysis was carried out using Graphpat Prism 6.0. 
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3 AAAG microsatellite in the ESRRG gene as a 
potential biomarker for prediction of breast 
cancer risk 
3.1 Introduction 
The oestrogen related receptor gamma (ESRRG) gene encodes for the ERRγ 
protein and is on chromosome 1q41 (Figure 3-1). A notably polymorphic AAAG 
microsatellite in the 5’ untranslated region (UTR) of this gene has previously 
been investigated. An association was found between the presence of long 
AAAG repeat lengths in the ERRγ gene and the risk of developing breast 
cancer by our group (Galindo et al., 2011). Our group has also previously 
demonstrated that 9 copies of the AAAG VNTR drives reporter gene 
expression in MCF-7 breast cancer cells (Galindo et al., 2011). In the present 
study I explored reporter gene expression with constructs containing 7, 9, 16 
and 19 copies of the AAAG VNTR. With the knowledge that oestrogen can 
drive the expression of ER+ breast cancer I also investigated the influence of 
the various repeats on reporter gene expression with exposure to oestrogen. In 
the quest for a novel biomarker to predict breast cancer risk I genotyped 
various alleles of the AAAG VNTR within a UK breast cancer cohort to find a 
link between allelic variation and breast cancer risk. 
 
Other studies have revealed germline variations in microsatellite regions linked 
to glioblastoma, ovarian and breast cancer (Fonville et al., 2015; Karunasena 
et al., 2014; McIver et al., 2014). Both breast and ovarian cancer account for 
the majority of cancer related deaths in women. Novel biomarkers could 
therefore help identify individuals at risk of these cancers and guide 
surveillance as early cancer detection is associated with a better overall 
outcome. Germline whole exome sequencing of both breast and ovarian 
cancer patients have revealed loci associated with cancer risk for both breast 
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and ovarian tumours. 30% of variants found in breast cancer exome 
sequencing analysis were also predictive of ovarian cancer risk and 70% of 
those identified for ovarian cancer are also associated with breast cancer risk 
(Fonville et al., 2015; Karunasena et al., 2014; McIver et al., 2014) 
Previous studies have examined the role of AAAG microsatellites in breast 
cancer in two cohorts of different ethnic backgrounds with conflicting results. In 
a study of an Iranian cohort breast cancer was linked to a lower copy number 
of the AAAG polymorphism in the intron of ESRRG. The allelic distribution 
ranged from six to eighteen repeats with nine repeats being the most common. 
AAAG repeats of six and seven were only found in the breast cancer patients 
linking these findings to breast cancer risk (Karimi et al., 2013). Whereas in an 
American study AAAG tandem repeats of 13 copies or longer located in the 
5′UTR region of the ESRRG gene was observed in women with breast cancer 
(allelic distribution ranging from five to 21 repeats with seven repeats being the 
most prevalent). Their cohort consisted of a population of mixed ethnicity 
(African-American, Hispanics, Caucasians, and Chinese women). No 
significant difference was found between the different ethnic backgrounds 
(Galindo et al., 2011). These conflicting reports may be attributed in part to 
differences in ethnicity. Further research needs to be undertaken in order to 
support this theory (Karimi et al., 2013). 
Interestingly varying copy numbers of the AAAG repeat within the P3 promoter 
region of the parathyroid hormone receptor 1 (PTHR1) gene have been shown 
to have a significant association with markers of bone desorption and adult 
height in an allele specific manner (Minagawa et al., 2002). 
Several studies have reported increased risk of breast cancer related to high 
ERRγ expression levels (Ao et al., 2008; Ariazi et al., 2002; Ijichi et al., 2011) 
whereas others report a negative correlation with breast cancer (Eichner et al., 
2010; Tiraby et al., 2011). 
 
 
  49 
A) 
 
B) 
   >>>>> ESRRG fwd >>>>                                      
TGAACCTAGGAGATAGAGGTTGCAGTGAGCCGAGATTGCGCCACTGCACTCCAGCCTGGG 
         *         *         *         *         *         * 
 
CAACAGAGTGAGATTCTGTCCCAAAGCCAAAAA[AAAG]AAATGCCTGCTGTAATGGGGT 
         *         *         *           *         *         
 
TGCAAAAACAAAATCTCAAAATGCTGTAGAAAAAATGCCTGCTGTAATGGGGTTGCAAAA 
 *         *         *         *         *         *        
 
ACAAAATCTCAAAATGCTGTAGAAAAATTATGTCATTTGTGTTTTAGTCATTAGATGTCC 
 *         *         *         *         *         *        
 
ATAGATTATTCAAGAATAAATATTAATACAAAAAATTGCATGTTACCAAAATGAGTTCTT 
 *         *         *         *         *         *        
 
GTGTTCCAAATAATTTGCATGGCATGACAAATAAATTATTGGCCTGGTTTCTAAAATGTG 
 *         *         *         *         *         *        
                   <<<<<< ESRRG rev <<<<< 
GTAGTTGTTTTGTTTTTTACCCTGATAGTGCAGAAGAAGAGTCC 
 *         *         *         *         *         *        
 
Figure 3-1: Gene map of ESRRG : A) (UCSC Genome Browser on Human 
Feb. 2009 (GRCh37/hg19) Assembly chr1: 216,675,576-217,500,000. 
Chromosomal position 1q41 highlighted on top. Graph adapted from UCSC 
Genome Browser): ESRRG gene locus with variants. The gene is located on 
the negative strand. Exons appear as vertical bars The (AAAG)n VNTR 
(chr1:217053466-217053469) spanning PCR is highlighted as a blue line. 
Possible mRNA transcripts collated at the bottom of the figure.  
B) ESRRG VNTR PCR: Sequence targeted by PCR primers for the AAAG 
VNTR in the first intron of ESRRG, PCR amplicon highlighted in blue. PCR 
primer (ESRRG fwd and ESRRG rev are indicated as arrows. The repetitive 
VNTR element (AAAG)n is highlighted in yellow and delineated by brackets.  
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The mechanism of activity of the ERRγ may be explained by the sequence 
overlap of the ERR and DNA binding and ligand binding domains of the ER 
(Huss et al., 2015). Both ERRα and ERRγ can substitute for the oestrogen 
receptor (ER) (Ariazi et al., 2006). The main difference between ER and ERR 
is that ERRs do not directly bind endogenous ER ligands or oestrogen but they 
can bind to oestrogen response elements (ERE) and oestrogen related 
response elements (ERRE). Co-activators such as peroxisome proliferator-
activated receptor γ (PPARγ), coactivator-1α (PGC-1α) and PGC-1β are found 
to be involved in transcription and modulation of ER signalling pathways and 
genes with functional ERREs. ERRγ which is a  downstream target of the ER  
recognises ERRE and EREs which are bound to ER and modulates ER 
mediated transcription and the oestrogen signalling pathway. ERR control of 
target gene transcription, coregulatory proteins, ligands and site of action partly 
overlaps with the ER’s implemented processes. In other words ERR can 
coregulate target genes with ER as well as regulating genes distinct from ER. 
Their exact mechanisms of action are yet to be fully elucidated (Foulkes et al., 
2004; Giguere, 2002; Howell et al., 2004; Ijichi et al., 2011; Lu et al., 2012).  
. 
3.2 Aims 
The aim of this chapter is to explore whether the AAAG VNTR could be a 
potential biomarker for breast cancer risk. I therefore performed genotype 
analysis of the AAAG VNTR in a female breast cancer cohort and matched 
controls to explore whether a difference in AAAG VNTR copy number 
differentiates between the groups. A second aim was to investigate whether 
the length of the AAAG VNTR affects ESRRG gene transcription in an 
oestadiol dependent manner. I addressed this by performing an in vitro 
luciferase reporter gene assay investigating the effect of different AAAG VNTR 
copy numbers on gene transcription with exposure to oestradiol.  
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3.3 Results  
3.3.1 Genotyping of AAAG microsatellite in ESRRG in a breast 
cancer cohort 
Genotype analysis was performed by simple observation in all four patient 
groups. Details of the groups are outlined in section 2.1.1. Allele calls were 
achieved for 44 cases in the BRCA1, 18 in the BRCA2, 54 in the BRCA 
negative and 26 in the control group. Due to low DNA concentrations and 
quality some of the samples could not be used and others could not be 
amplified by PCR. Nine different alleles were found which were numbered 1 to 
9, where 1 represented the shortest and 9 the longest VNTR length (figure 3-
1). The PCR products were not sequenced therefore the exact copy number is 
not known. 
I observed the frequency of individual alleles and genotypes (tables 3-1 and 3-
2, figure 3-3) in order to replicate the only two studies published on this subject 
which looked at the individual alleles in the AAAG VNTR and their association 
with breast cancer (Galindo et al., 2011) (Karimi et al., 2013). I found a clear 
pattern between specific alleles and particular groups within the cohort. The 
presence of alleles 2 and 3 were strongly associated with pathogenic BRCA1 
germline variant carriers. Allele 4 was significantly more common in the group 
of patients with pathogenic germline variants in BRCA2 . The BRCA negative 
group demonstrated a more widespread distribution. The control group were 
mostly in the 5 to 9 allele category with the number 9 allele only observed in 
the control group. The larger alleles were therefore more of a feature in the 
control group, mainly with allele number 6 and 7.  
The overall observation was that shorter repeats of the AAAG VNTR were 
associated with BRCA germline mutation carriers (BRCA1 and BRCA2) (alleles 
numbered 2 to 4) and longer repeats were a finding with the control group. The 
BRCA negative individuals did not appear to show a strong affinity with any 
particular allele number. 
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A significant correlation for alleles was observed for the BRCA1 group in a 
Spearman Rank correlation analysis (p=0.0209) and there was a strong trend 
for a correlation between allele distribution and the control group (p=0.0878). 
No correlation was found for the other groups. 
 
 
 
Figure 3-2: Genotyping of ESRRG AAAG VNTR PCR in a breast cohort: 
Representative agarose gel for the AAAG VNTR PCR (BRCA1 samples). A 2% 
gel was used to separate amplicons and a 100 bp DNA ladder (on right of gel 
image) was used to determine size. The shortest observed PCR amplicon 
spanning the VNTR in this cohort was called allele 1. G: Genotype, w : water 
control. 
 
 
  
  53 
Table 3-1: Allele pair frequency (including percentages) of the AAAG 
VNTR in the ERRG gene. Nine different alleles were observed where 1 is the 
shortest and 9 the longest. Genotype comprises the two alleles found in a 
sample. The allele numbering does not directly correspond to the number of 
AAAG 4bp VNTR repeats. Frequency distribution of observed patient genotype 
defined by the two alleles listed in the first column (x_y).  
 
 
  
 
Table 3-2: Individual allele frequencies (including percentages) of the 
AAAG VNTR in the ERRG gene. The BRCA1 and 2 groups are divided into 
subgroups with and without breast cancer (br-CA: breast cancer). 
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Figure 3-3: Graphs of allele frequency occurrence of the AAAG VNTR. 
Number of individual alleles and their distribution in each group. Numbers in 
brackets indicate patient group size) 
 
  
 
Figure 3-4: Graph of single allele distribution percentage frequencies 
with BRCA1 and 2 groups subdivided into groups with and without 
breast cancer.  
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Figure 3-5: Graph of allele pair distribution percentage frequencies. 
 
 
On assessment of allele pairs, I found homozygosity of the 2-2 and 3-3 alleles 
were the main feature of BRCA1, homozygosity with 4-4 for BRCA 2 and 
heterozygosity for 5-6, 6-7 and 7-9 allele combinations in the control group with 
allele number 9 only found in the control group in combination with alleles 
number 7 and 8 (figure 3-5). 
 
 
Table 3-3: Comparison of AAAG alleles within BRCA1, BRCA2, BRCA -ve 
and the control groups. The BRCA +ve groups were compared with each 
other in cancer and disease free subgroups of BRCA1 and 2 and in a 
combined BRCA +ve group with and without cancer. Statistical testing was 
performed using clump analysis using the Monte Carlo approach. 
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The BRCA 1 and 2 groups were further divided into individuals with and without 
a personal history of breast cancer (tables 3-1, 3-2, figure 3-4). Although this 
created even smaller numbers significant associations were made using a 
clump analysis (Table 3-3). Significant distributions were seen in alleles 
associated with breast cancer in both, the BRCA 1 and 2 positive groups. 
These findings mirrored the findings in the combined BRCA groups with 
homozygous 2-2, and 3-3 alleles in BRCA1 and homozygosity for allele 4 in 
BRCA 2 carriers (figure 3-5). An interesting observation was that a significant 
proportion of the number 3 allele in the BRCA 1 group was found in individuals 
with breast cancer (tables 3-1, 3-2 and figure 3-4). Clump analysis showed 
significant differences between all comparisons (table 3-3). 
Overall the findings of the distribution of AAAG VNTR in the different patient 
groups are interesting and could suggest an association for cancer risk which 
may be used as an additional predictive marker for breast cancer risk. As the 
main cancer finding was in the BRCA positive group clinically this may not add 
to the currently established, successful diagnostic tool used for identifying the 
BRCA mutation. However BRCA mutation carriers do not demonstrate a 100% 
disease penetrance therefore our findings could add additional evidence in 
calculating the cancer risk in the BRCA mutation carrier. This could give even 
more information to BRCA carriers about risk prediction during genetic 
counselling.     
The study will require reproduction in a larger cohort which may give more 
BRCA mutation carriers with cancer in order to make more statistically 
significant associations within this group. Allele analysis using capillary 
electrophoresis or sequencing to determine exact AAAG repeat numbers within 
each allele should also be carried out. In the current study a large number of 
comparisons have been made in a small sized cohort which could lead to false 
positive or negative results. 
If there had been an overwhelming characteristic allele distribution specifically 
for all individuals with cancer including the BRCA-ve group then a conclusion 
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may have been made to associate specific alleles to a general cancer risk 
prediction. This was not found on this occasion but has been reported by other 
groups (Galindo et al., 2011). 
3.3.2 Analysis of the reporter gene constructs containing 
varying lengths of the AAAG microsatellite under basal, 
vehicle (ethanol) and  treatment (17-β-oestradiol) 
conditions in MCF-7 cells  
 
 
Figure 3-6: Effect of AAAG copy number repeat on reporter gene 
expression. The graph displays the average fold difference in activity of the 
reporter gene constructs containing 7,9,16 and 19 copies of the AAAG 
microsatellite over the pGL3P (minimal SV 40 promoter) normalised to TK 
renilla luciferase activity in MCF-7 cells. N=4. Two-way ANOVA (analysis of 
variance) was used to calculate the significance of fold change between all 
copy numbers and pGL3P in basal, vehicle and treatment (10nM 17β-
oestradiol). (See table 3-4 for statistical results).  Significance in differences 
within the nine copy number group are indicated with ‘*’, where **** indicates a 
statistical p value smaller than 0.001 in a two-way ANOVA analysis (table 3-4). 
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Table 3-4: statistical significance between transfection groups. Table of 
significance of average fold change comparing the 7, 9, 16 and 19 copies of 
the AAAG VNTRs compared with each other and pGL3P. Statistical 
significance was calculated using two-way ANOVA.  
 
 
 
 
 
Four AAAG microsatellite variants (7, 9, 16 and 19 copies) were cloned into a 
vector with a minimal SV40 promoter (pGL3P) and analysed using reporter 
gene (luciferase) expression which was normalised to TK renilla in an MCF-7 
cell line. Transfections were performed in quadruplicate. The reporter gene 
constructs demonstrated variable levels of expression which were minimal in 
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the 7, 16 and 19 AAAG repeats. Activity was however significantly enhanced 
with the 9 copies of the AAAG repeat (figure 3-6).  
The reporter gene activity of the construct containing the 9 copies of the AAAG 
VNTR in MCF-7 cells showed a significant increase in basal conditions over 
pGL3P alone (P<0.0001). Activity with the vehicle conditions also significantly 
increased (P<0.0002) over pGL3P. When the MCF-7 cells were treated with 
17β-oestradiol the 9 copy AAAG VNTR showed a 26.5 fold (P< 0.0001) 
increase in reporter gene activity. The activity of the 9 copy repeat in all 3 
conditions (basal, vehicle, treatment) compared with the activity of the 7, 16 
and 19 VNTR repeats under the three conditions was found to be highly 
significant (table 3-4). 
 
3.4 Discussion 
This study has shown that the AAAG microsatellite in the 5’ UTR of the ERRG 
gene can support promoter gene activity. A variation of the VNTR copy number 
alone lead to an altered transcriptional activity, which was further enhanced 
upon stimulation with 17β-oestradiol. This supports findings of previous studies 
which also report similar gene expression in MCF-7 cells (Galindo et al., 2011) 
and an association between the repeat length of the AAAG microsatellite and 
transcription (Minagawa et al., 2002). 
 
We found significantly higher reporter gene activity specifically with the 9 
copies of the AAAG repeat in MCF-7 (ER+) breast cancer cells especially with 
exposure to oestrogen compared to the 7,16 and 19 repeat lengths. Ijichi et al 
explored ERRγ upregulation in various oestrogen environments. Their data 
showed that ERRγ was overexpressed in an oestrogen dose dependant 
manner, with oestrogen deprivation, in ER+ (MCF-7 cells) and ER- (MDA-MB-
23 cells) breast cancer cells (Ijichi et al., 2011).  
As Ijichi et al showed ERRγ expression in an oestrogen dose dependent 
manner the various lengths may also show differential reporter gene activity as 
a result of differing hormonal sensitivities and varying oestrogen dose 
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exposure. Variable hormone sensitivity could explain why 9 copies of the 
VNTR was the 2nd most common allele in the study by Galindo et al. (Galindo 
et al., 2011) and was the most commonly occurring allele in the cohort 
published by Karimi et al (Karimi et al., 2013) yet this did not translate into a 
marker for breast cancer risk in either study. In the American cohort published 
by Galindo 13 AAAG repeats and longer were found to be associated with 
breast cancer (Galindo et al., 2011). However in the Iranian study by Karimi 
shorter copy numbers (6 and 7 copies) were linked with breast cancer (Karimi 
et al., 2013). Genetic differences between ethnic backgrounds may be due to 
differences in genetic composition, lifestyle and environmental exposures. 
Patients who are carriers of the 9 copy allele will have varying exposure to 
oestrogen through lifestyle and reproductive history differences. This may 
translate into the resulting ERRγ activity caused by the 9 copy allele and 
therefore increase the risk of developing ER+ breast cancer. This also raises 
the question of whether the 7, 16 and 19 copies of the AAAG microsatellite 
may show greater activity in ER negative cells which may be explained by 
differences in transcription factor complements between ER positive and ER 
negative cell lines (Goldenberg and Froese, 1982). 
 
There is mounting evidence that ERRγ may be a marker for favourable 
outcome in breast cancer. ERRγ over expression is seen in less aggressive 
and ER/PR positive tumours. Its overexpression is also associated with 
overexpression of ErbB4 which is thought to indicate good clinical outcome as 
well (Ariazi et al., 2002).  4-hydroxytamoxifen (4-OHT) has been identified as a 
high affinity ligand for ERRγ causing the complex created by ERRγ and steroid 
receptor coactivator-1 to dissociate and as a result inhibit transcriptional 
activity of ERRγ. The discovery of 4-OHT antagonising ERRγ was made by 
peptide sensor, direct binding and cell based assays (Coward et al., 2001; 
Tremblay et al., 2001). The discovery of an alternative tamoxifen pathway 
involving ERRγ could aid patient selection for hormone therapy in the future as 
well as providing an alternative pathway to overcome tamoxifen resistance. It 
would be interesting to test the effect of the individual lengths of the VNTR on 
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this pathway to explore which of the repeat lengths specifically may be 
sensitive to anti-hormone therapy. 
 
Published data as to whether ERRγ expression has a positive or negative 
effect on breast cancer are conflicting (Ariazi et al., 2002; Galindo et al., 2011; 
Tiraby et al., 2011). One study which was performed using CHIP analysis and 
reporter gene activity in MDA-ERRγ cells found ERRγ to positively regulate E-
cadherin expression by direct binding of ERRγ via two ERREs in the second 
intron of the E-cadherin gene (CDH1) (Tiraby et al., 2011).  In the same study 
an ERRγ promoted E-cadherin expression and mesenchymal-to-epithelial 
transition (MET) was observed in tumour xenografts leading to diminished 
invasiveness and suppression of tumour growth. This finding also supports the 
role of the ERRγ as a marker of good prognosis. 
 
In summary ERRγ may play an active role in breast cancer through its 
overexpression specifically in the 9 copy VNTR (Galindo et al., 2011). Its 
response to oestrogen may also be a useful marker for favourable clinical 
outcome and hormone therapy response in ER positive breast cancer.  
 
Follow on work from this project should explore reporter gene activity of the 
various repeat lengths with exposure to varying concentrations of oestrogen in 
both ER+ and ER- breast cancer cells. This study should also be linked with 
the investigation of the effect of varying lengths of the VNTR on the tamoxifen 
pathway and breast cancer cells.    
 
Our genotyping analysis of the AAAG VNTR in a breast cancer cohort revealed 
an association between BRCA1 mutation carriers and allele numbers 2 and 3, 
BRCA2 mutation carriers and allele number 4 and the control group and allele 
numbers 5 to 9. Allele 9 was only observed in the control group. Allele number 
3 was observed in individuals with breast cancer within the BRCA1 group and 
allele number 4 was seen in breast cancer patients with a BRCA2 mutation. 
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Overall therefore longer repeats were observed in the control group and 
shorter VNTRs were found in the BRCA positive group. 
 
Our discovery in the pathogenic BRCA1 germline mutation carriers is of 
interest as these individuals tend to develop ER negative breast cancers which 
are difficult to treat due to their hormone insensitivity. BRCA1 related breast 
cancers also tend to present at a younger age and are generally of a higher 
grade.  This finding may elude to a potential marker of breast cancers which 
may be a challenge to treatment. Further analysis would be required not only to 
attempt to reproduce the findings in the BRCA1 group but also to identify 
exactly how many copies of the VNTR are represented by allele number 2 and 
3.  
 
ERRγ expression in the brain, skeletal muscle, heart, kidney, and retina 
suggests its involvement in maintenance and differentiation of these tissues in 
humans. There are several alternatively splice variants of the ERRγ mRNA in 
the 5’ UTR which are tissue specific. Over six different ERRG transcripts, some 
of which result in alternative protein isoforms have been reported (Heard et al., 
2000). The mechanisms involved are unclear. Two isoforms have been 
described to occur in the 5’ UTR and the first exon of ERRG. These may lead 
to alternative gene regulation which is dependent on the variable AAAG 
microsatellite lengths. This effect has been described as a possible explanation 
for the parathyroid hormone receptor 1 (PTHR1) gene which contains AAAG 
repeats in the promoter region which co-varies with adult height (Scillitani et al., 
2006). Another transcription factor which contains the AAAG VNTR which may 
bind to the 5′UTR of ERRG is the paired domain transcription factor PAX2 
which has been shown to activate specific target genes by direct binding 
(Bouchard et al., 2005; Galindo et al., 2011). Future studies could explore the 
AAAG microsatellite and its effect on transcription factor binding sites in the 
region for potential mechanisms of action. 
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Another explanation for differences in gene regulation and phenotype in cancer 
could be ‘over expansion’ of the microsatellite leading to misregulation of 
splicing. Ancestral lengthening of the VNTR coupled with mutations in the 
ERRG have also been suggested as a cause for variations in gene regulation. 
Alternatively the AAAG repeat may be located in an active RNA which has not 
been identified and may result in variation in activity based on repeat length 
(Galindo et al., 2011). 
 
In summary characteristic, significant allele distributions were identified for the 
BRCA positive and control group. Substantially more 2-2 and 3-3 homozygosity 
was seen in the BRCA 1 group with significantly more BRCA 1 individuals with 
breast cancer presenting with the 3 allele. The BRCA 2 group were 
homozygous for the 4 allele with a higher proportion of individuals with cancer 
compared to cancer free individuals with the mutation. Allele 4 may therefore 
be associated with a higher penetrance of cancer in individuals who are 
carriers of a BRCA 2 mutation. The length of the AAAG VNTR in ERRγ may 
also act as a biomarker to predict risk between the subtypes of breast cancer 
with differing hormonal status and sensitivities to oestrogen. 
 
A larger cohort with cross reference to clinical data and course of disease is 
required as a follow on to this research so that more in depth clinical 
associations can be made if present, with more statistical significance.  
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4  MIR137 VNTR as a potential biomarker for 
prediction of breast cancer risk 
4.1 Introduction 
In this chapter I address the potential role of a VNTR associated with MIR137 
in relation to breast cancer. Micro RNAs play a pivotal role in carcinogenesis 
and have also been discussed as potential therapeutic targets (Lee et al., 
2015b). MIR137 (1p22) is located in a CpG island (figure 4-1) and is of 
particular interest as it has been studied by our group in the context of 
schizophrenia (Warburton et al., 2016a; Warburton et al., 2016b; Warburton, 
2015) and extensively by others in relation to cancer. Some of these findings in 
cancer have been summarised and referenced in table 4.1. MIR137 has the 
hallmarks of a tumour suppressor and the downregulation of MIR137 has been 
proposed as being an early event in carcinogenesis (Huang et al., 2016). It is 
related to epigenetic regulation by promoter hypermethylation in a variety of 
cancers (Langevin et al., 2010; Zhang et al., 2018). Epigenetic modulation of 
micro RNAs has been described for a variety of cancers (table 4-1).  
 
Overexpression of MIR137 in cancer has demonstrated inhibition of cell 
invasion, cell cycle arrest, apoptosis and improved chemosensitivity through 
the effects of various targets (table 4-1). The silencing of miR-137 has been 
associated with aberrant DNA methylation in the region of the CpG island in 
oral squamous cell carcinoma (Kozaki et al., 2008) and lung cancer (Kang et 
al., 2015). In vitro experiments have shown that miR137 impairs proliferation 
and migration of breast cancer cells by targeting expression of the nuclear 
receptor oestrogen-related receptor alpha (ERRα) (Zhao et al., 2012). The 
possibility of reactivation of silenced MIR137 through EpiDrugs may present 
new therapy options based on the exploration of its role in the clinical setting. 
Epigenetic modifiers, have recently been introduced for anti-tumour therapy 
(Verma and Banerjee, 2015).  
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A) 
 
 
B) 
               >>>>> MIR137-F >>>>> 
GTAATCCGTATTATCCACCCAAGAATACCCGTCACCGAAGAGAGTCAGAGGACCAAGCTG 
         *         *         *         *         *         * 
 
[CCGCTGCCGCTGCTA]CTGCCGCCGCCGCCGCCACCAGAACTCTTGCTGCTCGCTGAGC 
          *          *         *         *         *         
 
CCGCCCCTGCCTGGGGATGGGCTGAGCTTGACCGGGACCATAAATCCATAACTCGATTTC 
 *         *         *         *         *         *          
 
CCTAAAGAAGGATCCAAAGCTGTGCTCGGCTGCTTCCTGCCCAAATCCAAATGGCCGCTC 
 *         *         *         *         *         *         
 
TATTTCCAATTctgaaagacaaatcacaaaatcaaatacttaacacagaagagtgctgtc 
 *         *         *         *         *         * 
 
tttccagtgaggagggaagatgtggcaaggctttttgggcacaagtgggagtgacaagta 
 *         *         *         *         *         * 
       <<<<< MIR137-R >>>>> 
accttcagtttacCTGGTGCTCTCCCAGTGCTTTCCT 
 *         *         *         * 
 
 
Figure 4-1: MIR137 gene map: A) (UCSC Genome Browser on Human Feb. 
2009 (GRCh37/hg19) Assembly chr1:98,510,446-98,512,572): chromosomal 
region flanking MIR137 (highlighted in light blue) featuring the CpG island 
(green), VNTRs and MIR137 amplicon (bottom line). B) MIR137 VNTR PCR: 
Sequence targeted by PCR primers for the internal MIR137 promoter (Imir137) 
(adapted genomic reference sequence: GRCh38.p12: 98046542-98046118). 
Upper case font indicates exons, lower case introns. PCR primer (MIR137-F 
and MIR137-R are indicated as arrows. The repetitive VNTR element is 
highlighted in yellow and delineated by brackets, the two CpG dinucleotides 
within the VNTR in bold and double underlined. Single underlined text marks 
the MIR-137 sequence. 
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Colleagues within our group have identified and validated an internal promoter 
(Imir137) adjacent to MIR137 in the MIR137-HG (Warburton et al., 2016a). 
This internal promoter contains a 15 bp VNTR which was found to contain 
several variants ranging from 4 to 12 copies. The most common variant 
identified was homozygosity for 4 copies of the VNTR in 55% of their 
schizophrenia cohort. The 12 copy variant was however rare therefore its role 
could not be further explored with significance. The 12 copy repeat within the 
ImiR VNTR was also found to be functionally distinct by reporter gene analysis. 
The copy number differentially modulated the ImiR137 reporter gene function: 
Mamdani and colleagues showed that 9 and 12 copies of the ImiR VNTR were 
associated with a decreased MIR137 transcription (Mamdani et al., 2013). This 
result was also partly reproduced by Warburton and colleagues who showed 
that 12 copies were differentially expressed (Warburton et al., 2016a). 
Other groups have also found repeat number variation (3 and 12 copies) to 
differentially alter the processing of mature miR-137 in a melanoma cell line 
model  (Bemis et al., 2008). 
Research performed by our group has created an interface between the role of 
MIR137 in both schizophrenia and breast cancer. Work originally performed by 
colleagues on schizophrenia has formed the bases for and inspired further 
work to investigate the role of MIR137 VNTR in breast cancer. 
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Table 4-1: Table of targets for MIR137 and their observed effects in 
cancer   
Cancer 
Type 
Validation method MIR137 
Target 
Effect of MIR137 up-
regulation  
References 
Pancreatic luciferase reporter 
assays, western blot 
in cell lines, tumour 
cells 
PTN inhibition of cell division, 
increased sensitivity to 
5FU chemotherapy, 
inhibition of tumour 
formation 
(Xiao et al., 
2014) 
Breast luciferase reporter 
assays in breast cells 
ERRα impaired proliferation 
and migration of cancer 
cells 
(Lee et al., 
2015b; 
Zhao et al., 
2012) 
Osteo-
sarcoma 
luciferase reporter 
assays in human 
tissue  
EZH2 
mRNA 
reduced cell viability and 
invasion 
(Li et al., 
2016) 
Gastric gastric cancer tissue Cdc42 Apoptosis, cell cycle G1 
arrest 
(Chen et al., 
2011a) 
Oral western blot, reporter 
assays 
BRD4 reduced cell proliferation, 
invasion and migration 
(Langevin et 
al., 2010) 
Colorectal luciferase reporter 
assay, methylation-
specific PCR, 
immune blotting in 
cell model, xenograft 
animal model 
Aurora A, 
MSI1 
inhibition of cell 
proliferation and tumour 
formation, apoptosis, 
G2/M arrest 
(Huang et 
al., 2016; 
Smith et al., 
2015) 
Lung luciferase activity in 
lung cancer cells and 
tissue (in vivo and in 
vitro) 
NUCKS1, 
Cdc42, 
CdK6 
inhibition of cell 
proliferation and 
migration, cell cycle 
arrest in G1 phase, 
chemotherapy, inhibition 
of angiogenesis 
(Shen et al., 
2016), (Zhu 
et al., 2013) 
Ovarian ovarian cancer cell 
line 
AEG-1 reduced in vitro cell 
growth, clonogenicity, 
cell cycle arrest (G1 
phase) 
(Guo et al., 
2013) 
Malignant 
melanoma 
Bioinformatics and S 
in vivo/vitro labelling 
analysis for dynamic 
proteomics (SiLAD) 
in melanoma cells 
PAK2 inhibition of cell 
proliferation 
(Hao et al., 
2015) 
Neuro-
blastoma 
luciferase reporter 
assays in SHEP and 
HEK293 cells 
KDM1A 
mRNA 
apoptosis , decreased 
cell viability and 
proliferation 
(Althoff et 
al., 2013) 
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The association of VNTR polymorphisms in carriers of pathogenic variants of 
the BRCA1/2 gene has been suggested as a modifier of ovarian and breast 
cancer risk (Cui et al., 2016; Phelan et al., 1996). Variations in a VNTR located 
in the promoter of the XRCC5 gene showed differential reporter gene 
expression and associations between BRCA1/2 groups and specific repeat 
numbers by genotype analysis (Cui et al., 2016). 
 
My study of the MIR137 VNTR in breast cancer has therefore been based on 
past studies which associate the role of MIR137 as a tumour suppressor in 
cancer including breast and the differential reporter gene expression of the 
MIR137 by variations in the VNTR repeat length shown by our group and 
others (Bemis et al., 2008; Warburton et al., 2015). Bemis et al reported this 
VNTR to contain two CpG dinucleotides and that variation in number of this 
15 bp repeat to be associated with CpG island length and modulation of miR-
137 function in a melanoma cell line (Bemis et al., 2008). The variations in the 
VNTR could affect the susceptibility of CpG islands to become 
hypermethylated or to be protected from this change (Ronneberg et al., 2008). 
A role for miR137 as a tumour suppressor is evident in several malignancies 
including, breast cancer (Lee et al., 2015b), pancreatic cancer (Xiao et al., 
2014), osteosarcoma cancer (Li et al., 2016),  gastric cancer (Chen et al., 
2011a),  oral cancer (Langevin et al., 2010),  ovarian cancer (Guo et al., 2013), 
lung cancer (Zhu et al., 2013) and in colon cancer (Smith et al., 2015). miR137 
is also involved in several significant pathways in melanoma development and 
progression (Hao et al., 2015). 
Downregulation of miR137 by promoter hypermethylation has been described 
in a variety of cancers and is believed to significantly contribute to 
carcinogenesis. miR137 has also been shown to be downregulated in 
neuroblastoma (Chen and Stallings, 2007) and high-grade astrocytic tumours 
further supporting its role in carcinogenesis (Godlewski et al., 2008). miR137 
may therefore have a protective role with regards to breast cancer (Lee et al., 
2015b).  
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The MIR137 VNTR is located at the internal promoter of the MIR137 host gene 
and consists of a 15 base pair sequence containing two CpG dinucleotides 
(Warburton, 2015).  
DNA methylation is a key feature of transcriptional regulation. In particular, 
methylation of gene promoters regulate transcription (Bird, 1986). High levels 
of DNA methylation in CpG islands located in promoter regions are typically 
associated with gene silencing and vice versa (Merlo et al., 1995; Veigl et al., 
1998). CpG islands are variably methylated however aberrant methylation at 
some CpG sites are linked with disease, in particular with cancer (Portela and 
Esteller, 2010; Robertson and Wolffe, 2000). 
The importance of epigenetics in cancers has been described for altered DNA 
methylation and histone modification. In cancer cells entire chromosomal 
segments may be densely packed as heterochromatin. Genes in these regions 
are inaccessible for the translation apparatus which consecutively leads to 
silencing of genes encoded on these stretches in the genome. Silencing by 
altered packing has been described for tumour suppressor genes and their 
target genes (Soria et al., 2010; Zhu et al., 2011). DNA methylation during 
replication is maintained by DNA methyl transferase (DNMT)1 whereas 
DNMT3a & DNMT3b are involved in de novo methylation (Paska and Hudler, 
2015; Sorm and Vesely, 1968). DNA methylation has been established as 
diagnostic, prognostic and predictive tumour markers (Kristensen and Hansen, 
2009; Mikeska et al., 2012). 
It is now also accepted that altered DNA methylation pattern may function as 
biomarkers for early detection of cancer. For instance in breast cancer BRCA1 
promoter hypermethylation detected in circulating DNA was associated with an 
increased risk for early onset of breast cancer (Wong et al., 2011). Epigenetic 
regulation of MIR137 through promoter hypermethylation has been described 
in a variety of cancers (Min et al., 2018; Vrba et al., 2013; Zhang et al., 2018) 
(table 4.1). The MIR137 internal promoter is located adjacent to a CpG island 
within the MIR137-HG (Warburton et al., 2015). The effect of the length of the 
VNTR on the CpG island was not addressed in this study. Varying lengths of 
CpG islands in promoter regions of tissue-specific genes are associated with 
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modulation of gene expression. Longer CpG islands appear to contain a high 
number of transcriptional start sites which may be responsible for regulation of 
the gene (Elango and Yi, 2011). 
 
4.2 Aims 
The aim of this chapter is to explore whether the MIR137 VNTR could be a 
potential biomarker for breast cancer risk. I therefore performed genotype  
analysis of the MIR137 VNTR by PCR in a female breast cancer cohort and 
matched controls. 
 
4.3 Results 
4.3.1 Four copy MIR137 VNTR homozygosity is less commonly 
observed in BRCA1/2 patients  
Genotype analysis was performed by simple observation in all four patient  
groups. Details of the groups are outlined in section 2.1.1. Allele calls were 
achieved for 40 samples in the BRCA1, 49 in the BRCA2, 97 in the BRCA 
negative and 98 in the control group. In the breast cancer cohort I observed 3 
to 12 repeats of the MIR137 VNTR (Figure 4.2). Initial inspection of the 
genotype figures showed that homozygosity for the 4 copy variant of the VNTR 
was the most frequent finding within all of the groups. The presence of the 
larger repeat number (12 copies) was rare (Figure 4.3 A; Table 4.2). 
The biallelic four copy VNTR of MIR137 was significantly less frequently 
observed in the BRCA1 cohort when compared to BRCA negative breast 
cancer patients, BRCA2 mutation carriers and healthy controls (two-way 
ANOVA) (Figure 4.3 B). Slightly more subjects were heterozygous for the 4 
copy and larger (10-12) copies within the BRCA1 cohort (7/40 (17.50%) 
subjects) compared to the control, BRCA negative and BRCA2 groups (2/98 
(2.04%), 2/97 (2.06%) and 0/49 (0%) respectively). This was only a trend and 
not found to be statistically significant (Table 4-2; Figure 4-3B) 
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Figure 4-2 Genotyping of MIR137 VNTR PCR in a breast cohort: DNA of 
healthy controls, BRCA negative patients and BRCA1/2 positive individuals 
were amplified using PCR. A 2% gel was used to separate amplicons and a 
100 bp DNA ladder (on right of gel image) was used to determine size. 
Genotype numbers represent number of repeats of the MIR137 VNTR. A) 
Example of genotype in the control group, B) Example of genotype in the 
BRCA negative group, C) Example of genotype in the BRCA1 positive group, 
D) Example of genotype in the BRCA2 positive group. w:water control. 
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Table 4-2: MIR137 VNTR Genotype analysis. Twelve different alleles were 
observed where 3 is the shortest and 12 the longest. Genotype designates the 
two alleles found in a sample. The allele numbering corresponds to the number 
of 15 bp VNTR repeats and are numbered 3-12. 
Frequency distribution of observed patient genotype defined by the two alleles 
listed in the first column (x_y). 
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Figure 4-3: Graph of allele frequency percentages of the VNTR in the 
MIR137 promoter. A) depicts the percentage frequency distribution of 
individual alleles in each group. B) shows the percentage of allele pairs 
(genotype) observed in each group listed in table 4.2. Significant variation of 
distribution between groups (two-way ANOVA: * p ≤ 0.05; *** p ≤ 0.001). 
Detailed allele pairs detected in BRCA1/2 positive, BRCA negative and control 
samples. BRCA1 N=40; BRCA2 N=49; BRCA negative N=97 and Controls 
N=98. 
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Table 4-3: MIR137 genotype of BRCA1 and 2 positive individuals with and 
without cancer. Frequency distribution of observed patient genotype defined 
by the two alleles listed in the first column (x_y). The allele numbers 
correspond to the number of copies of the 15 bp VNTR and are numbered 3-
12. 
 
 
 
 
4.3.2 Correlation of MIR137 VNTR with BRCA1 and BRCA2 pathogenic 
germline variant carriers and the occurrence of breast cancer in these 
patients 
Clump analysis (section 2.2.10, materials and methods chapter) was 
performed to maximise the chi-squared value of the multiple rare allele copy 
numbers (Table 4.4). Significance was reached when BRCA1 and BRCA2 
positive groups were combined and compared with the BRCA negative group 
(p=0.035). Statistical significance was also observed when the difference in 
allele frequency was compared between BRCA1 and BRCA2 mutation carriers 
(p=0.008). As it stands because of the small sample size these results will 
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have to be interpreted with caution. No further significance was reached when 
BRCA1 and 2 groups were further divided into individuals with and without 
cancer (Table 4.3). Again a larger cohort is required for future work on these 
groups.  
 
The data above shows a trend towards the presence of higher copy numbers 
(10-12 copies) of the VNTR in the BRCA1 positive group. This group was 
further divided into individuals with and without breast cancer for further 
comparison (table 4.3). Clump analysis was performed on individual BRCA1 
and 2 groups, on pooled data of BRCA1 and BRCA2 (i.e. BRCA positive) for all 
with and without cancer (table 4.4). None of the comparisons reached 
statistical significance. Some results within this table had a smaller sample 
mean compared to the hypothesized mean therefore a p value could not be 
calculated for these groups. 
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Table 4-4: Clump analysis for MIR137 VNTR genotype in a breast cohort 
 
 
Legend for table: Clump analysis using the Monte Carlo approach 
Significance was reached when BRCA negative was compared with the BRCA 
positive (BRCA1 and BRCA 2 cohorts were grouped together). P=0.035 (evidence). 
This gives an association with the MIR137 VNTR when BRCA positive is compared 
with BRCA negative. T3 (2x2 table constructed by comparing each non-rare column 
against the total of all remaining columns.), 10,000 simulations, chi-squared = 4.43, 1 
degree of freedom (df). Further significance was  associated with the BRCA1 cohort 
when compared with the BRCA2 group. P=0.008 (strong evidence). T2 (table 
compiled from an amalgamation of columns containing rare alleles), 10,000 
simulations, chi-squared=7.068, 1 df. The sections within the table that do not contain 
a p value are groups where the analysis could not calculate such values due to the 
small size of those groups.  
 
Abbreviations within table: w/o- without; CA- cancer (with reference to breast cancer); 
BRCA1 / 2 positive- BRCA1 and BRCA 2 cohorts grouped together. 
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4.3.2 MIR137 VNTR modifies CpG island length in silico 
In order to establish whether the VNTR copy number may influence the length 
of the CpG island which extends into MIR137 an in silico analysis was 
performed. Sequences including 5 kb upstream of the first copy of the VNTR 
and 5 kb downstream of MIR137 with four or twelve repeats of the VNTR were 
entered into EMBOSS CpGplot (Rice et al., 2000). A higher VNTR copy 
number gave a longer predicted CpG island, as would be expected. A 
predicted CPG island of 262 bp was calculated for the 4 copy VNTR whereas 
twelve repeats extended the predicted CpG island to 382 bp (Figure 4.4).   
A second simple nine base pair VNTR containing one CpG dinucleotide is 
located downstream of MIR137 in the CpG island in this region (RepeatMasker 
v4.0.7 Dfam_2.0 chr1:98045853-98045903). The influence of this repeat on 
the CpG island was not further investigated.  
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Figure 4-4: in silico CpG island prediction in MIR137: in silico CpG island 
prediction by EMBOSS Cpgplot (Rice et al., 2000) of the MIR137 sequence 
including 5kb upstream of the first VNTR and downstream of the MIR137 
coding sequence. A) MIR137 with four copies of the VNTR and B) twelve 
copies of the VNTR. First row: observed vs expected CpG; second row: 
percentage of CpGs; third line CpG site. Arrows indicate the region of the 
MIR137 VNTR. 
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4.4 Discussion 
I have addressed the repeat length variation of the VNTR in the internal 
promoter upstream of MIR137 (ImiR137). In silico analysis showed that the 
copy number variation of the MIR137 VNTR leads to an elongation of the 
predicted CpG island. This expansion of the CpG island as a result of a higher 
copy number of the VNTR which contains two CpG dinucleotides may be a risk 
predictor for carcinogenesis in carriers of pathogenic BRCA1/2 germline 
variants. A longer CpG island may predispose to hypermethylation of the 
ImiR137 promoter and a subsequent down regulation of miR137 and therefore 
of a loss of its tumour suppressor function.  
When addressing the VNTR allele types between our four patient cohorts we 
observed that the BRCA1 germline variant carriers showed a trend towards 
MIR137 VNTR alleles with higher copy numbers. This might be associated with 
a down regulation of miR137 as outlined above especially as the mechanisms 
of penetrance for BRCA1/2 pathogenic germline variant carriers with regards to 
development of breast cancer are still not entirely understood. A longer VNTR 
in the promoter of MIR137 may therefore be an additional risk factor for 
developing breast cancer in BRCA1/2 pathogenic germline variant carriers 
especially in the case of a loss of short allele as with loss of heterozygosity. 
The biallelic presence of the 4 copies of the VNTR was more frequently 
observed in the BRCA negative and the control group highlighting that these 
two groups may be less prone to a loss of miR137 expression related to 
ImiR137 promoter hypermethylation. Somatic miR137 promoter methylation 
analysis in BRCA1/2 and BRCA negative cancer patients would therefore be of 
interest.  
An association was observed between heterozygous higher copy numbers (10-
12 copies) and 4 copies in BRCA1 mutation carriers (table 4.2, figure 4.2). This 
observation however was similar in BRCA1 mutation carriers with and without 
a cancer diagnosis. Significance was not achieved on statistical analysis of the 
MIR137 VNTR and an association with cancer diagnosis using clump analysis.  
In terms of clinical impact the results of the BRCA1/2 positive groups with and 
without breast cancer are of particular interest as it could give an insight into 
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the effect of various repeat numbers on BRCA1/2 mutation penetrance. A 
larger study group in future work may give a more complete picture of 
BRCA1/2 penetrance if more individuals with breast cancer are found within 
the BRCA1/2 mutation carriers. Therefore if an association between specific 
VNTR lengths of the ImiR137 and breast cancer are found in BRCA1/2 
mutation carriers in future work then a biomarker to predict risk of breast 
cancer in this group could be a possibility. 
 
Functional analysis was also performed in vitro using reporter gene constructs 
to address the action of the MIR137 VNTRs as a regulatory domain by 
Mamdani an coworkers (Mamdani et al., 2013) and within our unit (Warburton 
et al., 2016a). Reporter gene analysis of the internal promoter demonstrated 
distinct VNTR repeat number supported expression in a neuroblastoma (SH-
SY5Y) cell line. The rare 12 copy variant was found to be functionally distinct 
from the 4 copy variant (Mamdani et al., 2013; Warburton et al., 2016a).  
These findings support further work to explore the potential role of miR137 in 
breast cancer and may link the effects of MIR137 silencing in breast and other 
cancers (table 4.1) through allele specific reporter gene activity, MIR137 
promoter methylation analysis and transcription levels. Other groups have also 
found repeat number variation (3 and 12 copies) to differentially alter the 
processing of mature miR137 in a melanoma cell line model (Bemis et al., 
2008). 
 
In conclusion VNTR copy number in the ImiR137 significantly differentiates 
between BRCA1/2 germline variant carriers and BRCA wild type individuals. 
However the observed ImiR137 VNTR copy number length did not differentiate 
between the cancer affected and tumour free BRCA1/2 individuals. Patient 
data and sample numbers were limited especially for the BRCA positive 
groups. The clinical significance of any future finding in a breast cancer group 
would be strengthened in a larger cohort with more clinical details.  
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The 4 copy allele was the most frequently occurring VNTR in all groups and the 
12 copy was rare. This mirrors the distribution of allele frequencies observed in 
a schizophrenia cohort investigated in our laboratory. Twelve copy alleles were 
seen in a heterozygous combination with lower copy numbers (mainly with 4 
copies). Twelve copies may be linked with cancer as the CpG island within the 
promoter region is increased in length with the presence of 12 copies. Longer 
CpG islands are associated with an increased likelihood of promoter 
hypermethylation and therefore an expansion of a CpG island may relate to 
silencing of a tumour suppressor gene (Elango and Yi, 2011). 
 
The hypothesis that the MIR137 VNTR may serve as a potential modifier for 
prediction of breast cancer in patients with pathogenic BRCA1/2 germline 
variants could not be verified in this study. However the results of this pilot 
study would suggest that further investigation for utility in a larger cohort should 
be conducted. 
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5 Final discussion 
Women have a 12% lifetime risk of developing breast cancer and this 
increases up to 80% in individuals carrying a BRCA1 or BRCA2 germline 
mutation (Rebbeck and Domchek, 2008). Screening for BRCA1/2 mutations is 
well established for prediction of familial breast and ovarian cancer risk. The 
penetrance of these mutations however are incomplete (Kuchenbaecker et al., 
2017). Other additional mutations and genetic variations may influence the 
level of penetrance as well as modifying the risk of developing breast cancer. 
One of the aims of my study was to explore the role of polymorphism in two 
candidate genes that may influence breast cancer progression. 
 
In both the MIR137 and AAAG VNTR studies associations were found mainly 
with specific VNTR variants and BRCA1/2 mutation carriers and in particular 
with females with cancer who are BRCA1 mutation carriers (AAAG VNTR). 
Breast cancer in BRCA1 mutation carriers can be difficult to treat as their 
cancers tend to be oestrogen receptor negative and therefore unlikely to 
respond to hormone therapy. They also present at a younger age often with a 
more aggressive tumour type. These women may benefit not only from more 
accurate prediction for cancer risk but also from even closer surveillance or risk 
reducing surgery at a younger age. Choosing a treatment option is a difficult 
decision to make for a multitude of reasons as previously outlined (section 1.5). 
The discovery of additional biomarkers to aid further risk determination is of 
great importance especially in the younger age group of BRCA positive 
individuals who may choose surveillance over risk reducing surgery (Johns et 
al., 2017). My study therefore highlights particularly promising discoveries 
where replication in a larger cohort is justified. 
 
In a reporter gene assay addressing the AAAG VNTR copy number length in 
ESRRG I found that oestrogen plays an important role in transcription 
regulation, which supports the important role of GxE in breast cancer. This may 
give further insight into the understanding of the biology of oestrogen related 
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carcinogenesis in breast tissue. This is significant in relation to women and 
their varying relationship and response to endogenous and exogenous sex 
hormones. Variations in breast cancer risk in general and oestrogen exposure 
in different ethnic groups are likely to be due to cultural differences, genetic 
variations and differing sensitivities to oestrogen (Gilliland et al., 1998; Hall et 
al., 2005; Rebbeck and Domchek, 2008). There is even more variability in 
reports of breast cancer risk amongst individuals with identical BRCA1/2 
mutations (Rebbeck and Domchek, 2008; Xie et al., 2018). Factors which can 
increase the risk of developing breast cancer due to increased exposure to 
oestrogen are very individual but may mirror the socioeconomic and cultural 
environment. This may also explain the differences in data for AAAG repeat 
number variation described in Iranian, American and British (this study) 
cohorts.  
 
The mechanisms involved in VNTR driven reporter gene expression in MIR137 
and ESRRG are still not clear.  In 2011 in a similar study the ESRRG gene was 
described to have two isoforms which were thought to result in alternate 
regulation of the gene under the influence of the varying length of the VNTR. 
Today eight transcription start sites and two additional isoforms have been 
found giving further possibilities for mechanism of action. This was also 
described with the parathyroid hormone gene where a variance of the VNTR 
co-varies with height (Scillitani et al., 2006). There are several candidate 
transcription factors and transcription start sites that could bind to the gene in 
the VNTR region of ESRRG based on repeat length. One transcription factor 
which has been suggested to bind directly to the AAAG VNTR is PAX2 
(Galindo et al., 2011). PAX2 has also been shown to bind to the ER and to 
supress ERRB transcription. This mechanism was found when the interaction 
of PAX2 with HER2 was investigated in relation to tamoxifen resistance 
(Hurtado et al., 2008). This could explain a possible mechanism for how 
variance in the AAAG VNTR of ESRRG and its gene product are involved in 
oestrogen signalling pathways. Further investigation to explore possible 
mechanisms of action is required. 
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Discovery of genetic variants to date is just the tip of the iceberg which 
represents the human genome and disease processes involved. Even more 
important than the identification of genetic polymorphisms is the continuing 
progress in technological capabilities to make these discoveries. Many genetic 
variants discovered so far remain of uncertain clinical relevance with regards to 
their risk related to cancer development. This might result from a selection bias 
of patients involved in these studies (i.e. recruited from specialist clinics) and 
therefore some variants may be associated with an over estimated cancer risk 
(Easton et al., 2015). A significant number of studies have also been 
performed on European women and this raises doubt as to whether relative 
risks calculated in this population can be applied to other nationalities who may 
have differences in breast cancer incidence. Genetic counselling and risk 
prediction is difficult and also requires consideration of non-genetic factors 
such as ethnicity as well as lifestyle and hormonal exposure.  
Testing for multiple mutations can be informative in updating risk prediction 
scoring (Easton et al., 2015). In a GWAS study on BRCA1 mutation carriers 
Couch and colleagues demonstrated that the absolute risk was significantly 
modified compared to published figures when they identified new loci 
associated with breast cancer risk (Couch et al., 2013). Panel testing of 
multiple genes are currently in clinical use and can be quite informative 
especially when combined with clinical and epidemiological data. With the 
falling costs and increased speed of whole exome and whole genome 
sequencing (WES / WGS) and the improvement of bioinformatics capacities 
required for analysis of the large data generated the identification of individuals 
with increased cancer risk and disease penetrance will become identifiable. A 
concern with such thorough analysis is the identification of several germline 
variants of uncertain significance which may be difficult to interpret in the 
clinical setting unless combined with other mutations to give a more meaningful 
risk prediction (Easton et al., 2015; Evans et al., 2017). We are already 
entering the next generation of medical practice with the 100,000 Genomes 
project (Public Health England, 2017b). This is a project which has been set up 
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by the NHS with the aim of transforming the way we diagnose and deliver 
patient care. The target set is to sequence 100,000 genomes from 
approximately 70,000 patients with cancer, infectious and rare diseases as well 
as their families. These specific groups have been selected as such advances 
in genomic technology would benefit these patients and the NHS the most. 
This project and genome sequencing is already leading to new and more 
accurate diagnoses as well as changes in treatment provision, in other words 
more stratification of patient care. 
Whole exome sequencing is cheaper than whole genome sequencing and can 
therefore be applied to a broader cohort. Even though WES will not cover the 
same extend as WGS it is a powerful tool and a suitable investigation for 
discovery of novel genes and for mutation analysis. Niguidula et al performed a 
survey which assessed the effect of WES data on clinical decision making and 
healthcare impact. They found that WES data directly lead to changes in 
treatment management, cessation of unnecessary diagnostic testing, 
recruitment of patients into appropriate clinical trials and referral of patients to 
more appropriate specialist care based on their diagnosis. It is of note that 90% 
of patients also opted for further testing for secondary/incidental findings which 
was beneficial for testing potential family members who were genetic mutation 
carriers. In patients with a definitive diagnosis derived from WES unnecessary, 
expensive, time consuming, potentially invasive testing was stopped. Even 
though the single test may appear expensive the financial overall benefit from 
thorough testing may reduce the overall costs (Niguidula et al., 2018).  
 
The findings of this project and related work performed by others within our 
group has revealed further possibilities for future work to continue the search 
for novel biomarkers for the prediction of breast cancer risk. Investigating the 
tumour suppressor RE1 Silencing Transcription Factor (REST) also known as 
Neuron Restrictive Silencing Factor (NRSF) would be another natural 
progression from work already performed by our group on breast cancer and 
neurodegenerative disorders and with the overlap of biology between the two. 
Our team have found that the internal ImiR137 promoter can be regulated 
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partly by REST and miR137 expression can be affected by the genotype of the 
VNTR in the promoter as well as by environmental factors. This mechanism 
could play an influential role in schizophrenia (Warburton et al., 2015). Loss of 
REST has also been associated with a subset of aggressive breast cancers 
which have a particularly high rate of recurrence and lymph node metastasis. 
Wagoner and colleagues investigated the expression of REST and it’s target 
genes in aggressive breast cancer. They found loss of function of REST and 
expression of a truncated REST splice variants associated with increased 
breast cancer risk. Interestingly this truncated REST isoform is usually found in 
the brain following epileptic fits (Wagoner et al., 2010). 
 
Cancer is a complex disease which is influenced by genetic variations, 
epigenetic factors (e.g. DNA methylation) as well as environmental/life style 
choices such as oestrogen exposure. In order to establish any further 
biomarkers modifying factors other than genetic variations would need to also 
be considered such as ethnic background, lifestyle, hormone and reproductive 
history as well as the age of the cohort. 
 
In conclusion, my findings suggest that VNTRs within MIR137 and the ESRRG 
could be potential modifiers for prediction of breast cancer risk in BRCA1 and 
BRCA2 pathogenic mutation carriers. The data will require replication with 
additional significance in a larger cohort before it may be considered for 
implementation in clinical practice. 
 
Despite new genetic advances within the NHS which will revolutionise 
medicine we still need to individualise risk by considering modifying factors. 
This will not only guide the healthcare professionals in offering stratified 
treatment options but more importantly it will empower patients whilst they 
make the most important and difficult decisions of their lives. It will be 
interesting to observe how changes in risk prediction with more accurate risk 
calculation will affect the clinician’s advice to patients and the patient’s ultimate 
decision. Rebbeck and colleagues summarised such uncertainties rather 
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precisely. ‘Will a mutation carrier make a different decision based on a 40% 
lifetime risk of breast cancer versus a 60% lifetime risk?’ Will doctors ever give 
the advice of a mastectomy or the option of surveillance with great certainty? 
(Rebbeck and Domchek, 2008). Only time will tell how the outcome of these 
advances will evolve. 
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